AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON FEBRUARY 19, 2020
 
Registration No. 333-233585
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM S-1
AMENDMENT 3
 
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
 
POTNETWORK HOLDINGS, INC.
 (Exact Name of Registrant as specified in its charter)
 
Colorado
 
2833
 
46-5470832
(State or other Jurisdiction
of Incorporation or Organization)
 
(Primary Standard Industrial
Classification Code Number)
 
(I.R.S. Employer
Identification No.)
 
3531 Griffin Road, Fort Lauderdale, FL 33312
Tel: 800-433-0127
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
 
Kevin Hagen, CEO
3531 Griffin Road
Fort Lauderdale, FL
Tel: 800-433-0127
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
 
With copies to
:
 
Jonathan D. Leinwand, P.A.
18851 NE 29th Ave., Suite 1011
Aventura, FL 33180
Phone: 954-903-7856
 
Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this registration statement.
 
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. x
 
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
 
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
 
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
¨
Accelerated filer
¨ 
Non-Accelerated filer
¨ 
Smaller reporting company
x
 
Emerging Growth Company
x
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) ¨
 
 
 
 
 
CALCULATION OF REGISTRATION FEE
 
Title of Each Class of
Securities to be Registered
 
Amount to be Registered (1)(2)
 
 
 
Offering
Price
Per Share
 
 
Aggregate
Offering
Price
 
 
Amount of Registration
Fee
 
 
Shares of Common Stock, par value $0.00001 per share, underlying notes
(3)
 
 
223,000,000
 
 
$
.02
 
 
$
4,460,000
 
 
$ 1,297.33
 
 
Total
 
 
223,000,000
 
 
$
.02
 
 
$
4,460,000
 
 
$ 1,297.33
 
__________ 
(1)
The shares of common stock being registered hereunder are being registered for resale by the selling stockholder named in the accompanying prospectus.
 
 
(2)
Pursuant to Rule 416 under the Securities Act of 1933, as amended, the shares being registered hereunder shall be deemed to cover additional securities to be offered to prevent dilution and thus includes such indeterminate number of shares of common stock as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends or other similar transactions.
 
 
(3)
Represents shares of common stock issuable upon conversion of notes, offered by the selling stockholder named in this prospectus.
 
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.
 
 
2
 
 
  
The information in this prospectus is not complete and may be changed. The selling stockholder may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
 
PRELIMINARY PROSPECTUS
 
SUBJECT TO COMPLETION
DATED February 19, 2020
 
POTNETWORK HOLDINGS, INC.
 
223,000,000
SHARES OF COMMON STOCK
 
$.02 PER SHARE
 
This prospectus relates to the sale, from time to time, by the selling stockholder identified in this prospectus (the “
Selling Stockholder
”) of up to 223,000,000 shares of our common stock, par value $0.00001 per share, at a fixed price of $.02 per share, consisting of 223,000,000 shares of common stock issuable upon conversion of outstanding notes (the “
Resale Shares
”). All of the Resale Shares are held by the Selling Stockholder pursuant to the securities purchase agreements, dated October 25, 2018 and February 7, 2019.
 
The Selling Stockholder may sell some or all of their Resale Shares from time to time in the principal market on which the stock is traded. The offering price bears no relationship to our assets, book value, earnings or any other customary investment criteria. We will not receive any proceeds from the sale of the Resale Shares by the Selling Stockholder. The Resale Shares may be sold by the Selling Stockholder to or through underwriters or dealers, directly to purchasers or through agents designated from time to time. For additional information regarding the methods of sale you should refer to the section entitled “
Plan of Distribution
” beginning on page 5 of this prospectus.
 
We will bear all costs relating to the registration of the Resale Shares. All selling and other expenses incurred by the Selling Stockholder will be borne by the Selling Stockholder.
 
Our common stock is quoted on the OTC Marketplace under the symbol “POTN.” On August 26, 2019, the closing price of our common stock was $.0487.
 
Investing in our common stock is highly speculative and involves a high degree of risk. See the section entitled “
Risk Factors
” appearing on page 8 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.
 
You should rely only on the information contained in this prospectus or any prospectus supplement or amendment thereto. We have not authorized anyone to provide you with different information.
 
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
 
The date of this prospectus is _____ , 2020
 
 
3
 
 
 
 
 
6
 
 
7
 
 
8
 
 
16
 
 
16
 
 
18
 
 
22
 
 
28
 
 
30
 
 
30
 
 
31
 
 
32
 
 
35
 
 
36
 
 
36
 
 
37
 
 
F-1
 
 
 
F-16
 
 
4
 
 
You should rely only on the information contained in this prospectus. We have not, and the Selling Stockholder has not, authorized any person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus is not an offer to sell, nor is the Selling Stockholder seeking an offer to buy, securities in any state where the offer or solicitation is not permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the common stock. Our business, financial condition, results of operations, and prospects may have changed since such date.
 
The distribution of this prospectus and the issuance of the securities in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the issuance of the securities and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, the securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.
 
 
5
 
 
 
This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in the common stock of PotNetwork Holdings, Inc. (referred to herein as the “Company,” “POTN,” “we,” “our,” and “us”). You should read this entire prospectus carefully, including “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition or Plan of Operations,” and our financial statements and the related notes appearing at the end of this prospectus, before making an investment decision.
 
Overview
 
The Company’s primary business is conducted through its subsidiary, First Capital Venture Co., whose subsidiary, Diamond CBD, Inc. (“Diamond CBD”) is engaged in the development and sales of hemp-derived CBD oil containing products. Generically, products containing hemp-derived CBD are sold as dietary supplements.
 
Hemp-derived CBD is distinguishable from CBD derived from marijuana. Hemp-derived CBD contains not more than 0.3 percent of THC, while marijuana contains in excess of this amount. Marijuana is regulated under the Controlled Substances Act. We do not believe that our hemp-derived CBD products are regulated under the Controlled Substances Act, but under the Agricultural Act of 2018, known as the “Farm Bill”
 
The Company believes that all products produced and marketed by it, are in compliance with the Farm Bill and all other federal and state law and regulation.
 
Diamond CBD’s products are marketed under 15 brand names, including “Diamond CBD”, “Chill”, “Relax”, “MediPets” and the premium “Meds BioTech” label, as well as many others. In total, Diamond CBD offers over 800 products in variations by flavor, concentration and size that are sold over a nationwide distribution network of over 550 distributors and resellers that sell to thousands of brick-and-mortar retailers and online merchants. The overall product line, because of its size, is constantly in flux as new products are added and products are culled based on several factors including, but not limited to, consumer acceptance, inventory levels, and replacement as the result of incremental improvement.
 
Diamond CBD also offers for sale a majority of its products direct to consumers via its website, http://www.diamondcbd.com.
 
Corporate History
 
PotNetwork Holdings, Inc., (the “Company” or the “Registrant”) was originally incorporated in Nevada in 1996 as H P Capital Corp. The Company redomiciled in Wyoming in 2004 and changed its name to My Medical CD, Ltd. From May 2016 to March 2017, the Company was known as SND Auto Group, Inc. On March 3, 2017, the Company redomiciled in Colorado, and changed its name to PotNetwork Holdings, Inc.
 
On January 30, 2017 the Company acquired via reverse triangular merger 100% of the ownership interest of the privately-held First Capital Venture Co., a Florida corporation. First Capital Venture Co. is the owner of Diamond CBD, Inc. selling numerous CBD Oil products at both wholesale and retail. Pursuant to the Share Exchange and Reorganization Agreement, the First Capital Venture Co. shareholders exchanged their shares which they held in First Capital Venture Holdings Co. for an aggregate total of 50,000 Class A preferred shares of the Company, wherein the shareholders would own 100% of this class of stock of the Company (the “Class A Preferred Shareholders”), which in the aggregate conferred voting control of the Company. First Capital Venture Co. became a wholly-owned subsidiary of the Company as result of the transaction.
 
Pursuant to a Stock Purchase Agreement dated June 8, 2017, the Company acquired all the capital stock of PotNetwork Media Group, Inc., a Nevada corporation (“PMG”), in exchange for 3,000,000 shares of the Company’s common stock issued to the shareholders of PMG, and the cancellation of a $50,000 promissory note between the Company and PMG. As a result, PMG became a wholly-owned subsidiary of the Company. PMG is the owner of the website www.potnetwork.com. Potnetwork.com is an informational website on the overall cannabis industry and does not market any products. PMG is also the publisher of a magazine, “PotNetwork .
 
 
6
 
 
The Company has two (2) wholly-owned subsidiaries:
 
 
·
First Capital Venture Co., a Florida corporation which has as its wholly-owned subsidiary, Diamond CBD, Inc., a Delaware corporation
 
·
PotNetwork Media Group, Inc., a Nevada corporation, operator of the website, PotNetwork.com.
 
 
Securities Offered by the Selling Stockholder
 
223,000,000 shares of the Company’s common stock
 
 
 
Price Per Share
 
$.02
 
 
 
Gross Proceeds
$4,460,000
 
 
 
Common stock Outstanding Before the Offering (1)
 
700,836,384
 
Common stock Outstanding After the Offering
 
923,836,384
 
Quotation of Common stock
 
The Company’s common shares are quoted on the OTC Markets Pink Tier
 
Use of Proceeds
 
We are not selling any shares of the common stock covered by this Prospectus. Consequently, we will not receive any of the offering proceeds from the sale of the shares of common stock registered and covered by this Prospectus.
 
Risk Factors
 
The common stock offered hereby involves a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investment. See “Risk Factors” beginning on page 8.
_________ 
(1)
Based on 700,836,384 shares outstanding as of January 31, 2020.
 
 
7
 
 
 
An investment in our common stock involves a high degree of risk. An investor should carefully consider the following risk factors and the other information in this registration statement before investing in our common stock. Our business and results of operations could be seriously harmed by any of the following risks.
 
Our industry may become subject to expanded regulation and increased enforcement by the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC)
 
The FDA under the Federal Food, Drug, and Cosmetic Act regulates the formulation, manufacturing, packaging, labeling, and distribution of food, dietary supplements, drugs, cosmetic, medical devices, biologics, and tobacco products. Our hemp-derived CBD products are not intended to be drugs. Accordingly, we have not been required to obtain FDA approval for our existing hemp-derived CBD products. Moreover, the regulatory status of hemp-derived CBD products are in a state of flux as FDA attempts to determine the appropriate manner in which to regulate these products. Thus, the regulatory approach is still evolving, and we may be required to seek FDA’s approval to market food and dietary supplements containing hemp-derived CBD. It is also possible that FDA may simply issue a regulation setting forth the conditions in which such products may be marketed, or it may simply prohibit these products. However, because FDA’s regulatory process is in its infancy, we cannot predict the likely outcome. In addition, the FTC under the Federal Trade Commission Act (“FTC Act”) requires that product advertising is truthful, substantiated and non-misleading. We believe that our advertising meets these requirements. However, the FTC may bring a challenge at any time to evaluate our compliance with the FTC Act.
 
As disclosed herein, our Company received a Warning Letter from the FDA and the FTC regarding the advertising and labeling claims for our products. FDA also takes the position that certain ingestible products containing CBD may only be marketed if approved as a “drug.” Although we dispute the issues identified by FDA and FTC, we have adjusted the advertising and labeling claims raised in the letter to be in material compliance with the FDCA and the FTC Act.
 
Despite our corrective actions in response to the Warning Letter, as a Company regulated by the FDA and the FTC, we may be subject to enforcement actions by either agency. Enforcement actions by FDA may include a seizure of our products, an injunction issued by a federal court preventing us from selling our products, civil monetary penalties, or, in egregious circumstances, criminal prosecution. The potential enforcement actions that may be taken by the FTC include an injunction in a Federal District Court, an Administrative Cease and Desist Order, or civil monetary penalties. Finally, it is possible that FDA may decide to prohibit the use of hemp-derived CBD in foods and/or dietary supplements.
 
We have a limited operating history and operate in a new industry, and we may not succeed.
 
The consumer products business is a highly competitive and risky business, and such competition from companies much bigger than us could adversely affect our operating results.
 
We compete with many national, regional and local businesses. We could experience increased competition from existing or new companies in our channel, which could create increasing pressures to grow ours. If we are unable to maintain our competitive position, we could experience downward pressure on prices, lower demand for our products, reduced margins, the inability to take advantage of new business opportunities and the loss of channel share, which would have an adverse effect on our operating results. Other factors that could affect our business are:
 
 
·
Consumer tastes
 
·
National, regional or local economic conditions
 
·
Disposable purchasing power
 
·
Demographic trends; and
 
·
The price of special ingredients that go into our products.
 
 
8
 
 
Increases in the cost of ingredients, labor and other costs could adversely affect our operating results.
 
Our principal products contain hemp-derived CBD oil. Increases in the cost of ingredients in our products could have a material adverse effect on our operating results. Significant price increases, market conditions, weather, acts of God and other disasters could materially affect our operating results. An increase in our operating costs could adversely affect our profitability. Factors such as inflation, increased labor and employee benefit costs and increased energy costs may adversely affect our operating costs. Many of the factors affecting costs are beyond our control and we may not be able to pass along these increased costs to our customers.
 
We do not have long-term contracts with many of our suppliers, and as a result they could seek to increase prices or fail to deliver.
 
We typically do not rely on written contracts or long-term arrangements with our suppliers. Although we have not experienced significant problems with our suppliers, our suppliers may implement significant price increases or may not meet our requirements in a timely fashion, if at all. The occurrence of any of the foregoing could have a material adverse effect on our operating results.
 
Any prolonged disruption in the operations of any of our packaging facilities could harm our business.
 
Any prolonged disruption in the operations of any facilities that perform our packaging, whether due to technical or labor difficulties, destruction or damage to the facility, real estate issues or other reasons, could result in increased costs and reduced revenues and our profitability and business results could be harmed.
 
Loss of key personnel or our inability to attract and retain new qualified personnel could hurt our business and inhibit our ability to operate and grow successfully.
 
Our ability to successfully grow our brand depends on our ability to attract and retain professionals with talent, integrity, enthusiasm and loyalty to our corporate team. If we are unable to attract or retain key personnel, our profitability and growth potential could be harmed.
 
We may not be able to adequately protect our intellectual property, which could harm the value of our brand and branded products and adversely affect our business.
 
We depend in large part on our brand and branded products as well as on our proprietary processes and believe that they are very important to our business. We rely on a combination of trademarks, copyrights, trade secrets and similar intellectual property rights to protect our brand and branded products. The success of our business depends on our continued ability to use our existing trademarks in order to increase brand awareness and further develop our branded products in both domestic and international markets. We have registered, or will register, certain trademarks in the United States and may elsewhere. We may not be able to adequately protect our trademarks and our use of these trademarks may result in liability for trademark infringement, trademark dilution or unfair competition. We may from time to time be required to institute litigation to enforce our trademarks or other intellectual property rights, or to protect our trade secrets. Such litigation could result in substantial costs and diversion of resources and could negatively affect our sales, profitability and business results regardless of whether we are able to successfully enforce our rights.
 
Our annual and quarterly financial results are subject to significant fluctuations depending on various factors, many of which are beyond our control, which could adversely affect our ability to satisfy our debt obligations as they become due.
 
Our sales and operating results can vary significantly from quarter to quarter and year to year depending on various factors, many of which are beyond our control. These factors include:
 
 
·
Variations in the timing and volume of our sales
 
·
The timing of expenditures in anticipation of future sales
 
·
Sales promotions by us and our competitors
 
·
Changes in competitive and economic conditions generally
 
·
Foreign currency exposure
 
 
9
 
 
Consequently, our results of operations may decline quickly and significantly in response to changes in order patterns or rapid decreases in demand for our products. We anticipate that fluctuations in operating results will continue in the future. The Company’s operating results may vary. We may incur net losses. The Company expects to experience variability in its revenues and net profit. While we intend to implement our business plan to the fullest extent we can, we may experience net losses. Factors expected to contribute to this variability include, among other things:
 
 
·
The general economy
 
·
The regulatory environment pertaining to our products
 
·
Climate, seasonality and environmental factors
 
·
Consumer demand
 
·
Transportation costs
 
·
Competition in products
 
You should further consider, among other factors, our prospects for success in light of the risks and uncertainties encountered by companies that, like us, are in their early stages. For example, unanticipated expenses, problems, and technical difficulties may occur and they may result in material delays in the operation of our business, in particular with respect to our new products. We may not successfully address these risks and uncertainties or successfully implement our operating strategies. If we fail to do so, it could materially harm our business to the point of having to cease operations and could impair the value of our common stock to the point investors may lose their entire investment.
 
We may require additional capital to finance our operations in the future, but that capital may not be available when it is needed and could be dilutive to existing stockholders.
 
We may require additional capital for future operations. We plan to finance anticipated ongoing expenses and capital requirements with funds generated from the following sources:
 
 
·
Cash provided by operating activities
 
·
Available cash and cash investments
 
·
Capital raised through debt and equity offerings
 
Current conditions in the capital markets are such that traditional sources of capital may not be available to us when needed or may be available only on unfavorable terms. Our ability to raise additional capital, if needed, will depend on conditions in the capital markets, economic conditions and a number of other factors, many of which are outside our control. Accordingly, we cannot assure you that we will be able to successfully raise additional capital at all or on terms that are acceptable to us. If we cannot raise additional capital when needed, it may have a material adverse effect on our liquidity, financial condition, results of operations and prospects. Further, if we raise capital by issuing stock, the holdings of our existing stockholders will be diluted.
 
If we raise capital by issuing debt securities, such debt securities would rank senior to our common stock upon our bankruptcy or liquidation. In addition, we may raise capital by issuing equity securities that may be senior to our common stock for the purposes of dividend and liquidating distributions, which may adversely affect the market price of our common stock. Finally, upon bankruptcy or liquidation, holders of our debt securities and shares of preferred stock and lenders with respect to other borrowings will receive a distribution of our available assets prior to the holders of our common stock. Additional equity offerings may dilute the holdings of our existing stockholders or reduce the market price of our common stock, or both.
 
 
10
 
 
Our stock price has been extremely volatile, and our common stock is not listed on a national stock exchange; as a result, stockholders may not be able to resell their shares at or above the price paid for them.
 
The market price of our common stock as has been historically volatile and could be subject to significant fluctuations due to changes in sentiment in the market regarding our operations or business prospects, among other factors. Further, our common stock is not listed on a national stock exchange; we intend to list the common stock on a national stock exchange once we meet the entry criteria. An active public market for our common stock currently exists on the OTC Markets (www.otcmarkets.com) but may not be sustained. Therefore, stockholders may not be able to sell their shares at or above the price they paid for them.
 
Among the factors that could affect our stock price are:
 
 
·
Industry trends and the business situation of our suppliers
 
·
Actual or anticipated fluctuations in our quarterly financial and operating results and operating results that vary from the expectations of our management or of securities analysts and investors
 
·
our failure to meet the expectations of the investment community and changes in investment community recommendations or estimates of our future operating results
 
·
Announcements of strategic developments, acquisitions, dispositions, financings, product developments and other materials events by us or our competitors
 
·
Regulatory and legislative developments
 
·
Litigation
 
·
General market conditions
 
·
Other domestic and international macroeconomic factors unrelated to our performance
 
·
Changes in key personnel
 
Sales by our stockholders of a substantial number of shares of our common stock in the public market could adversely affect the market price of our common stock.
 
A substantial portion of our total outstanding shares of common stock may be sold into the market at any time, or a substantial portion of our total outstanding shares of preferred stock may be converted to common stock and sold into the market at any time. Some of these shares are owned by the management of the Company, and we believe that such holders have no current intention to either convert their preferred stock into common stock or to sell a significant number of shares of their common stock into the market. If all of the major stockholders were to decide to sell large amounts of stock over a short period of time such sales could cause the market price of our common stock to drop significantly, even if our business is performing well.
 
The conversion of the Note held by the Selling Stockholder may depress our stock price and dilute your ownership of the company.
 
We are registering 223,000,000 common shares to be issued upon the conversion of a Note for resale by the Selling Stockholder. The conversion price of the principal of the Note is $0.45 per share of common stock, as may be adjusted pursuant to its terms.
 
To the extent that the Note is converted, dilution to our stockholders will occur. Moreover, the terms upon which we will be able to obtain additional equity capital may be adversely affected, since the holder of the Note can be expected to convert it at a time when we would, in all likelihood, be able to obtain any needed capital on terms more favorable to us than the conversion terms provided by the Note. Further, in the event the conversion price of the Note is lower than the actual trading price on the day of conversion, the holder could immediately convert the Note, which would have a dilutive effect on the value of the outstanding common shares. Furthermore, the significant downward pressure on the trading price of our common stock when the Note holder converts the Note and sells the common shares received on conversion could encourage short sales by the holders of the Note or other stockholders. This would place further downward pressure on the trading price of our common stock. Even the mere perception of eventual sales of common shares issued on the conversion of the Note could lead to a decline in the trading price of our common stock.
 
 
11
 
 
Our financial statements may not be comparable to those of other companies.
 
Pursuant to Section 107(b) of the JOBS Act, we have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2) of The JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result, our financial statements may not be comparable to companies that comply with public company effective dates, and our stockholders and potential investors may have difficulty in analyzing our operating results if comparing us to such companies.
 
The success of our new and existing products and services is uncertain.
 
We have committed, and expect to continue to commit, significant resources and capital to develop and market existing product enhancements and new products. We cannot assure you that we will achieve market acceptance for all of our products, or of new products that we may offer in the future. Moreover, these new products may be subject to significant competition with offerings by new and existing competitors. In addition, new products and enhancements may pose a variety of challenges and require us to attract additional qualified employees. The failure to successfully develop and market these new products or enhancements could seriously harm our business, financial condition and results of operations.
 
Our business is dependent upon continued market acceptance by consumers.
 
We are substantially dependent on continued market acceptance of our products by consumers. Although we believe that our products in the United States are gaining increasing consumer acceptance, we cannot predict that this trend will continue in the future.
 
As we expand our operations, we may be unable to successfully manage our future growth.
 
Since inception, our business has grown. This growth has placed substantial strain on our management, operational, financial and other resources. If we are able to continue expanding our operations in the United States and in other countries where we believe our products will be successful, as planned, we may experience periods of rapid growth, which will require additional resources. Any such growth could place increased strain on our management, operational, financial and other resources, and we will need to train, motivate, and manage employees, as well as attract management, sales, finance and accounting, international, technical, and other professionals. In addition, we will need to expand the scope of our infrastructure and our physical resources. Any failure to expand these areas and implement appropriate procedures and controls in an efficient manner and at a pace consistent with our business objectives could have a material adverse effect on our business and results of operations.
 
Any future litigation could have a material adverse impact on our results of operations, financial condition and liquidity, particularly since we do not currently have director and officer (“D&O”) insurance. Our lack of insurance may also make it difficult for us to retain and attract talented and skilled directors and officers. While we intend to apply for D&O insurance, we cannot guarantee that such application will be accepted.
 
Despite our significant efforts in product quality control, we face risks of litigation from customers and others in the ordinary course of business, which may divert our financial and management resources. Any adverse litigation or publicity may negatively impact our financial condition and results of operations.
 
Claims of illness or injury relating to product quality or handling are common in the consumer products industry. While we believe our processes and high standards of quality control will minimize these instances, there is always a risk of occurrence, and so despite our best efforts to regulate quality control, litigation may occur. In that event, our financial condition, operating results and cash flows could be harmed.
 
 
12
 
 
From time to time we may be subject to litigation, including potential stockholder derivative actions. Risks associated with legal liability are difficult to assess and quantify, and their existence and magnitude can remain unknown for significant periods of time. To date we have no directors and officers liability (“D&O”) insurance to cover such risk exposure for our directors and officers. Such insurance generally pays the expenses (including amounts paid to plaintiffs, fines, and expenses including attorneys’ fees) of officers and directors who are the subject of a lawsuit as a result of their service to the Company. While we intend to attempt to obtain such insurance, there can be no assurance that we will be able to do so at reasonable rates or at all, or in amounts adequate to cover such expenses should such a lawsuit occur. While neither Colorado law nor our articles of incorporation or bylaws require us to indemnify or advance expenses to our officers and directors involved in such a legal action, we expect that we would do so to the extent permitted by Colorado law. Without D&O insurance, the amounts we would pay to indemnify our officers and directors should they be subject to legal action based on their service to the Company could have a material adverse effect on our financial condition, results of operations and liquidity. Further, our lack of D&O insurance may make it difficult for us to retain and attract talented and skilled directors and officers, which could adversely affect our business.
 
Our prior operating results may not be indicative of our future results.
 
You should not consider prior operating results with respect to revenues, net income or any other measure to be indicative of our future operating results. The timing and amount of future revenues will depend almost entirely on our ability to sell our products to new customers. Our future operating results will depend upon many other factors, including:
 
 
·
The level of product and price competition,
 
·
Our success in expanding our distribution network and managing our growth,
 
·
Our ability to develop and market product enhancements and new products,
 
·
The timing of product enhancements, activities of and acquisitions by competitors,
 
·
The ability to hire additional qualified employees, and
 
·
The timing of such hiring and our ability to control costs.
 
Our current Board of Directors consists of only two people
 
Gary Blum and Kevin Hagen are our sole directors.
 
We only have one outside Director which could create a conflict of interests and pose a risk from a corporate governance perspective.
 
 
Our Board of Directors consists of only two directors, only one of whom is an outside or independent director. The lack of independent directors may prevent the Board from being independent from management in its judgments and decisions and its ability to pursue the Board responsibilities without undue influence. For example, an independent Board can serve as a check on management, which can limit management taking unnecessary risks. Furthermore, the lack of independent directors creates the potential for conflicts between management and the diligent independent decision-making process of the Board. Furthermore, our lack of outside directors deprives our company of the benefits of various viewpoints and experience when confronting the challenges we face. With only a single independent director sitting on the Board of Directors, it will be difficult for the Board to fulfill its traditional role as overseeing management.
 
Requirements associated with being a reporting public company require significant company resources and management attention.
 
We have filed a Form 10 registration statement with the U.S. Securities and Exchange Commission (“SEC”). Since the Form 10 became effective, we have been subject to the reporting requirements of the Exchange Act and the other rules and regulations of the SEC relating to public companies. We are working with independent legal, accounting and financial advisors to identify those areas in which changes should be made to our financial and management control systems to manage our growth and our obligations as an SEC reporting company. These areas include corporate governance, internal control, internal audit, disclosure controls and procedures and financial reporting and accounting systems. We have made, and will continue to make, changes in these and other areas, including our internal control over financial reporting. However, we cannot provide assurances that these and other measures we may take will be sufficient to allow us to satisfy our obligations as an SEC reporting company on a timely basis.
 
 
13
 
 
In addition, compliance with reporting and other requirements applicable to SEC reporting companies will create additional costs for the Company and will require the time and attention of management and may require the hiring of additional personnel and legal, audit and other professionals. We cannot predict or estimate the amount of the additional costs we may incur, the timing of such costs or the impact that our management’s attention to these matters will have on our business.
 
Our preferred shareholders have voting control.
 
The holders of our Series A Preferred Stock have voting control over the Company. As a result, they have the ability to control substantially all matters submitted to our stockholders for approval including:
 
 
·
Election of our board of directors;
 
·
Removal of any of our directors;
 
·
Amendment of our articles of incorporation or bylaws; and
 
·
Adoption of measures that could delay or prevent a change in control or impede a merger, takeover or other business combination involving us.
 
In addition, each share of Class A preferred stock is convertible into 0.01% of the total number of shares of Common Stock outstanding at the Conversion Time. On any matter presented to the shareholders of the Corporation for their action or consideration at any meeting of shareholders of the Corporation (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of Series A Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series A Preferred Stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Articles of Incorporation, holders of Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.
 
Based on the preceding and upon a total quantity of issued and outstanding shares of common stock as of September 30, 2019 of 700,836,384, each share of Class A preferred stock is convertible into 70,084 shares of common stock. As a result, if each of the two Class A preferred shareholders listed were able to convert 100% of each’s Class A preferred stock, Kevin Hagen, who holds 20,742 Class A preferred shares, would receive 1,453,682,328 shares of common stock; and Elinor Taieb, who holds 13,547 Class A preferred shares, would receive 949,427,948 shares of common stock.
  
Our preferred stock may have rights senior to those of our common stock which could adversely affect holders of common stock.
 
Our articles of incorporation give our Board of Directors the authority to issue additional series of preferred stock without a vote or action by our stockholders. The Board also has the authority to determine the terms of preferred stock, including price, preferences and voting rights. The rights granted to holders of preferred stock in the future may adversely affect the rights of holders of our common stock. Any such authorized class of preferred stock may have a liquidation preference - a pre-set distribution in the event of a liquidation - that would reduce the amount available for distribution to holders of common stock or superior dividend rights that would reduce the amount of dividends that could be distributed to common stockholders. In addition, an authorized class of preferred stock may have voting rights that are superior to the voting right of the holders of our common stock.
 
We are an emerging growth company and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors.
 
We are an emerging growth company, as defined in the JOBS Act, and we are eligible to take advantage of certain exemptions from various reporting requirements applicable to other public companies, but not to emerging growth companies, including, but not limited to, a requirement to present only two years of audited financial statements, an exemption from the auditor attestation requirement of Section 404 of the Sarbanes-Oxley Act, reduced disclosure about executive compensation arrangements pursuant to the rules applicable to smaller reporting companies and no requirement to seek non-binding advisory votes on executive compensation or golden parachute arrangements, although some of these exemptions are available to us as a smaller reporting company (i.e. a company with less than $75 million of its voting equity held by affiliates). We have elected to adopt these reduced disclosure requirements. We cannot predict if investors will find our common stock less attractive as a result of our taking advantage of these exemptions. If some investors find our common stock less attractive as a result of our choices, there may be a less active trading market for our common stock and our stock price may be more volatile.
 
 
14
 
 
We do not expect to pay any cash dividends in the foreseeable future.
 
We intend to retain our future earnings, if any, in order to reinvest in the development and growth of our business and, therefore, do not intend to pay dividends on our common stock for the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, and such other factors as our board of directors deems relevant. Accordingly, investors may need to sell their shares of our common stock to realize a return on their investment, and they may not be able to sell such shares at or above the price paid for them.
 
We can sell additional shares of common stock without consulting stockholders and without offering shares to existing stockholders, which would result in dilution of existing stockholders’ interests in the Company and could depress our stock price.
 
Our Articles of Incorporation authorize 1,000,000,000 shares of common stock, of which 626,656,621 were outstanding as of December 31, 2018 and 700,706,621 are outstanding on June 30, 2019; 50,000 shares of series A preferred stock, of which 39,839 shares were outstanding as of December 31, 2018, and 34,289 are outstanding on June 30, 2019. Moreover, our Board of Directors is authorized to issue additional shares of our common stock and preferred stock. Although our Board of Directors intends to utilize its reasonable business judgment to fulfill its fiduciary obligations to our then existing stockholders in connection with any future issuance of our capital stock, the future issuance of additional shares of our common stock or preferred stock convertible into common stock would cause immediate, and potentially substantial, dilution to our existing stockholders, which could also have a material effect on the market value of the shares.
 
Because we will be subject to “penny stock” rules, the level of trading activity in our stock may be reduced.
 
Broker-dealer practices in connection with transactions in “penny stocks” are regulated by penny stock rules adopted by the Securities and Exchange Commission. Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on some national securities exchanges). The penny stock rules require a broker-dealer to deliver to its customers a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market prior to carrying out a transaction in a penny stock not otherwise exempt from the rules. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and, if the broker-dealer is the sole market maker, the broker-dealer must disclose this fact and the broker-dealer’s presumed control over the market, and monthly account statements showing the market value of each penny stock held in the customer’s account. In addition, broker-dealers who sell these securities to persons other than established customers and “accredited investors” must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. Consequently, these requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security subject to the penny stock rules.
 
Financial Industry Regulatory Authority (FINRA) sales practice requirements may also limit your ability to buy and sell our stock, which could depress our share price.
 
FINRA rules require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares, depressing our share price.
 
 
15
 
 
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
 
This prospectus contains forward-looking statements. Such statements include statements regarding our expectations, hopes, beliefs or intentions regarding the future, including but not limited to statements regarding our market, strategy, competition, development plans (including acquisitions and expansion), financing, revenues, operations, and compliance with applicable laws. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. Factors that could cause actual results to differ materially from such forward-looking statements include the risks described in greater detail in the section entitled “Risk Factors” beginning on page 8.
 
All forward-looking statements in this document are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise after the date of this prospectus, except where applicable law requires us to update these statements. Market data used throughout this prospectus is based on published third party reports or the good faith estimates of management, which estimates are based upon their review of internal surveys, independent industry publications and other publicly available information. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
 
In addition, in this prospectus, we use words such as “anticipate,” “believe,” “plan,” “expect,” “future,” “intend,” and similar expressions to identify forward-looking statements.
 
 
We will not receive any proceeds from the sale or other dispositions of the shares covered hereby by the Selling Stockholder.
 
We will pay for the expenses of this offering, except that the Selling Stockholder will pay any broker discounts or commissions or equivalent expenses and expenses of Selling Stockholder legal counsel applicable to any sale of the shares.
 
 
Our common stock began trading on the Pink Tier of the OTC Markets Group, Inc. under the symbol “POTN”. Prior to that, our common stock traded on the Pink Tier of the OTC Markets Group, Inc. The following table sets forth the high and low sale prices for our Common Stock for each quarterly period within the two most recent fiscal years. There has been minimal reported trading to date in the Company’s common stock.
 
 
16
 
 
The following table sets forth the high and low closing bid prices for our Common Stock for the fiscal quarter indicated as reported on the OTC. The quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.
 
 
 
Price Range
 
Period
 
High
 
 
Low
 
Year Ended December 31, 2016:
 
 
 
 
 
 
First Quarter
 
$ .25
 
 
$ .01
 
Second Quarter
 
$ .04
 
 
$ .001
 
Third Quarter
 
$ .025
 
 
$ .0022
 
Fourth Quarter
 
$ .0065
 
 
$ .002
 
Year Ending December 31, 2017:
 
 
 
 
 
 
 
 
First Quarter
 
$ .0698
 
 
$ .0025
 
Second Quarter
 
$ .0995
 
 
$ .017
 
Third Quarter
 
$ .0839
 
 
$ .0436
 
Fourth Quarter
 
$ .1251
 
 
$ .052
 
Year Ending December 31, 2018:
 
 
 
 
 
 
 
 
First Quarter
 
$ .0957
 
 
$ .1199
 
Second Quarter
 
$ .413
 
 
$ .194
 
Third Quarter
 
$ .3912
 
 
$ .2206
 
Fourth Quarter
 
 
.2761
 
 
 
.0836
 
Year Ending December 31, 2019:
 
 
 
 
 
 
 
 
First Quarter
 
$ .1750
 
 
$ .0980
 
Second Quarter
 
$ .1650
 
 
$ .0577
 
Third Quarter
 
$ .1049
 
 
$ .0375
 
Fourth Quarter
 
$
.052
 
 
$
.021
 
 
As of January 3, 2019, there were approximately 2,288 holders of record of our common stock.
 
Dividends.
We have never declared or paid any cash dividends on our common stock nor do we anticipate paying any in the foreseeable future. We expect to retain any future earnings to finance our operations and expansion. The payment of cash dividends in the future will be at the discretion of our Board of Directors and will depend upon our earnings levels, capital requirements, any restrictive loan covenants and other factors the Board considers relevant.
 
 
17
 
 
PLAN OF OPERATION
 
The following Management’s Discussion and Analysis of Financial Condition and Plan of Operations (“MD&A”) is intended to help you understand our historical results of operations during the periods presented and our financial condition. This MD&A should be read in conjunction with our consolidated financial statements and the accompanying notes to consolidated financial statements and contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. All forward-looking statements speak only as of the date on which they are made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made.
 
PotNetwork Holdings, Inc., (the “Company” or the “Registrant”) was originally incorporated in Nevada in 1996 as H P Capital Corp. The Company redomiciled in Wyoming in 2004 and changed its name to My Medical CD, Ltd. In 2017, the Company redomiciled in Colorado, and changed its name to PotNetwork Holdings, Inc. The Company’s primary operational business is conducted through its subsidiary, First Capital Venture Co., whose subsidiary, Diamond CBD, Inc. (“Diamond CBD”) is engaged in the development and sales of hemp-derived CBD oil containing products.
 
Results of Operations during the year ended December 31, 2018 as compared to the year ended December 31, 2017
 
For the years ended December 31, 2018 and December 31, 2017, we generated revenues of $25,583,761 and $14,388,204, respectively, a 78% increase year over year. At year-end 2017, the Company was marketing 106 products under its various brand names. At year-end 2018, as the result of the addition of over 500 new items and SKU’s of existing products, the Company was marketing over 600 under its various brands. The increase is attributable to increased marketing expenditures, an expanded product line and an increase in sales personnel. Sales and marketing expenses increased from $3,491,555 for the year ended December 31, 2017 to $7,894,819 for the year ended December 31, 2018, an increase of 126%. General advertising expense increased from $577,586 to $1,967,766 year-over-year, an increase of 240%, and trade show expenses increased from $1,935,458 to $3,491.555 year-over-year, an increase of 63%. Additionally, in 2018, the Company invested $712,515 in direct marketing, and incurred an increase in merchant services expenses from $460,423 to $700,866. General and administrative expenses rose from $735,175 to $811,420 during the same period for an increase of 10%, primarily due to an increase in payroll during the period. As the Company continues to increase revenues in 2019, it is anticipated that overall expenses will continue to increase specific to marketing and increased payroll or related expense.
 
Our Gross Profit from the sale of all products for the year ended December 31, 2018 and December 31, 2017 was $8,959,433 and $5,069,933 respectively, or a slight reduction from 35.24% to 35.02%. Continued growth of the consumer market for CBD products and anticipated increases in competition are anticipated to continue to create pressure on gross profit margins. Conversely, the expanded market is creating beneficial price fluctuations in the costs of ingredients as sources of supply expand which we believe will enable us to sustain comparable margins in the year ahead.
 
Our Net Profit for the year ended December 31, 2018 and December 31, 2017 decreased from $301,603 to $242,634, a decrease of 19.6%, as a substantial portion of gross profit was reinvested into sales and marketing.
 
 
18
 
 
Liquidity and Capital Resources
 
As of December 31, 2018, we had $5,214,529 in total assets including cash and cash equivalents of $584,425 and $4,630,104 in advances and accounts receivable, as compared to $1,806,342 in total assets including of cash and cash equivalents of $254,571 and $1,551,771 in advances and accounts receivable as of December 31, 2017. The increase is attributable to the adoption of the drop ship fulfillment model wherein advances are prepaid to the drop shipper. At December 31, 2018, unused advances paid to the drop shipper totaled $4,289,928, prepaid other expenses were $220,901.77 including $150,000 in prepayments for advertising material production, plus prepaid trade show expenses.
 
As of December 31, 2018, we had total liabilities of $4,082,195 consisting of accounts payable of $469,821, notes payable of $3,573,974 and an amount due a third party of $38,400. As of December 31, 2017, we had total liabilities of $2,171,978 including accounts payable of $270,980 and notes payable of $1,655,624 and an amount due a third party of $245,374. The increase in accounts payable is commensurate with our increase in revenue. Notes payable increased due to the Company selling a total of $2,225,000 in convertible notes during 2018. The reduction in the amount due to third parties between 2018 and 2017 is due to the conversion by two third parties of two 2016 convertible promissory notes in their entirety, leaving only the aggregate $38,400 balance at the end of 2018 (See Note 10 of the “Notes to the Financial Statements”). The remaining amount due third parties pertains to those two certain convertible promissory notes that are disputed and cited in the court cases described in Note 12 of the “Notes to the Financial Statements”.
 
Cash Flow from Operating Activities
 
Net cash from operations for the year ended December 31, 2018 was $(925,483) as compared to ($117,910) for the year ended December 31, 2017.
 
Cash Flow from Investing Activities
 
Net cash provided by investing activities for the year ended December 31, 2018 was $1,255,336 as compared to $224,841 for the year ended December 31, 2017.
 
Cash Flow from Financing Activities
 
Net cash provided by financing activities for the year ended December 31, 2018 was $0 as compared to $0 for the years ended December 31, 2017.
 
Results of Operations during the nine months ended September 30, 2019 as compared to the period ended September 30, 2018.
 
For the nine-month period ended September 30, 2019 and 2018 we had revenues of $14,157,742 and $17,967,189 respectively.
 
Our Gross Profit from the sale of all products for the nine-month period ended September 30, 2019 and September 30, 2018 was $5,600,056 and $7,695,108 respectively, or a decrease of 27%. Continued growth of the overall consumer market for CBD products and anticipated increases in competition are anticipated to continue to create pressure on gross profit margins. Conversely, the expanded market is creating beneficial price fluctuations in the costs of ingredients as sources of supply expand which we believe will enable us to sustain comparable margins in the year ahead.
 
 
19
 
 
Our Net Profit for the nine-month period ended September 30, 2019 compared to September 30, 2018 decreased to $(384,025) from $357,563, a decrease of 207%, attributable to the decrease in revenues and gross profit and an increase in interest expense.
 
Operating expenses for the nine-month period ended September 30, 2019 compared to September 30, 2018 decreased to $5,736,099 as compared to $7,325,012, a decrease of 21.7% attributable to a decrease in sales and marketing expense from $6,615,125 in the first nine months of 2018 to $5,108,343 during the same period in 2019.
 
Total expenses for the nine-month period ended September 30, 2019 were $5,984,081 with interest expense being $247,982 compared to $7,337,145 with interest expense of $12,133 for the comparable period of 2018.
 
Liquidity and Capital Resources
 
Assets increased from $5,214,530 at the Company’s fiscal year end of December 31, 2018 to $6,332,571 at September 30, 2019. The increase in the assets is attributable to an increase in accounts receivable and an increase in prepaid expenses, primarily an increase in advances paid to the drop shipper.
 
Liabilities increased from $4,082,195 as at December 31, 2018 to $5,388,236 as at September 30, 2019. The increase is mainly attributed to loans to the Company for its operating activities.
 
Cash Flow from Operating Activities
 
Net cash from operations for the nine-month period ended September 30, 2019 was ($1,938,272) as compared to $101,858 for the same period in 2018.
 
Cash Flow from Investing Activities
 
Net cash provided by investing activities for the nine-month period ended September 30, 2019 was $396,025 as compared to 2,444,714 for the same period in 2018.
 
Cash Flow from Financing Activities
 
Net cash provided by financing activities for the nine-month period ended September 30, 2019 was $1,463,002 as compared to $2,138,495 for the same period in 2018.
 
Off-Balance Sheet Arrangements
 
There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources.
 
Critical Accounting Policies and Estimates
 
This discussion and analysis of our financial condition and results of operations are based on our financial statements that have been prepared under accounting principle generally accepted in the United States of America. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
 
A summary of significant accounting policies is included in Note 2 to the consolidated financial statements included in this Registration Statement. Of these policies, we believe that the following items are the most critical in preparing our financial statements.
 
 
20
 
 
USE OF ESTIMATES: Management uses estimates and assumptions in preparing these financial statements in accordance with U.S. generally accepted accounting principles. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses.
 
REVENUE RECOGNITION - DIAMOND CBD BUSINESS
 
Revenue from sale of goods is measured at fair value of the consideration received or receivable and is recognized in the statement of comprehensive income of the Company when significant risks and rewards of the ownership of the goods have been transferred to the buyers. The Company applied the five step model of revenue recognition under ASC 606 to its ecommerce platform. The following describes each step of ASC606 and how the Company applied it making its revenue recognition determination:
 
Step 1: “Identify the contract with a customer”:
 
A.
The Company’s ecommerce website makes the offer to the customer.
 
 
B.
The customer chooses the product(s) and quantities of each. 
 
 
C.
The customer enters its credit card information.
 
 
D.
The contract between the company and the customer is concluded when the authorization is taken vis-à-vis the merchant account which processes the credit card payment. 
 
Step 2: “Identify the performance obligations in the contract”. The Company ships the merchandise and subsequently records the customer payment.
 
Step 3: “Determine the transaction price”. The website states each product’s regular price, and applicable sale price which is the amount that the customer pays the company.
 
Step 4: “Allocate the transaction price to the performance obligations in the contract”. The company’s ecommerce platform applies any quantity discount or other discount offered by the Company automatically.
 
Step 5: “Recognize revenue when the entity satisfies a performance obligation”. The Company records the sale upon the order’s shipping, identified by a tracking number.
 
ACCOUNTS RECEIVABLE: Accounts Receivable (AR) is the payment which the Company will receive from its customers who have purchased its goods & services in the last month of the year and on credit terms. Usually the credit period is short, approximately a few days.
 
ASSESSMENT OF COLLECTABILITY:
 
·
Receivables supervisor is authorized to collect delinquent accounts
 
·
The Treasurer has the authority to assign accounts to a third party for collection
 
·
Recording of Accounts Receivable: All amounts due on physical delivery of the merchandise from the drop shipper, must be promptly recorded as an accounts receivable. Each account receivable must be recorded and maintained until payment is received or the recorded amount is written off or extinguished.
 
 
·
An adequate provision for doubtful accounts must be established. When all reasonable efforts fail to collect an account receivable and it has been approved for write off, the related provision for doubtful accounts should be reduced.
 
 
·
Control and Subsidiary Accounts: The accounting system incorporates control accounts, where applicable, to ensure the completeness and accuracy of individual accounts. The Receivables supervisor must maintain subsidiary accounts for individual debtors in a manner that discloses, at a given point in time, the aggregate amount owed by each debtor as well as individual amounts making up the aggregate amount. Monthly, the subsidiary accounts for each accounts receivable must be reconciled with the control account.
 
 
·
Checks that are returned from the bank as nonnegotiable are assessed a returned cheque charge. If there are 2 cheques returned from the same customer within a month, no further cheques will be accepted from the customer unless the cheques are certified, until there is an acceptable payment history for a further one year period.
 
 
·
Statements to Debtors: Statements must be issued to debtors, on a monthly basis, providing meaningful and concise information on the status of their debts.
 
 
·
Accounts receivable are considered overdue when a debtor does not pay or resolve the debt within 30 days from the invoice date or a written request for payment to the debtor.
 
 
·
All actions taken to collect overdue accounts must be documented.
 
 
·
If there is no response after the initial contact at the 30-day point (within 30-day period 60 days from date of invoice), accounts will be forwarded to Treasury Staff to take prompt and vigorous action to collect overdue accounts receivable.
 
 
·
Accounts receivable, in most cases, should be at least 30 days overdue (i.e., 60 days after invoice notification), before staff advises debtors that their accounts are overdue and that the accounts may be:
   
 
21
 
 
 
o
turned over to a private collection agency;
 
o
 subject to legal action;
 
o
credit privileges will be revoked; and/or account may be suspended.
 
Most Recent accounting pronouncements
 
Refer to Note 2 in the accompanying consolidated financial statements.
 
Impact of Most Recent Accounting Pronouncements
 
There were no recent accounting pronouncements that have had a material effect on the Company’s financial position or results of operations.
 
 
22
 
 
 
PotNetwork Holdings, Inc., (the “Company” or the “Registrant”) was originally incorporated in Nevada in 1996 as H P Capital Corp. The Company redomiciled in Wyoming in 2004 and changed its name to My Medical CD, Ltd. From May 2016 to March 2017, the Company was known as SND Auto Group, Inc. On March 3, 2017, the Company redomiciled in Colorado, and changed its name to PotNetwork Holdings, Inc.
 
On January 30, 2017 the Company acquired via reverse triangular merger 100% of the ownership interest of the privately-held First Capital Venture Co., a Florida corporation. First Capital Venture Co. is the owner of Diamond CBD, Inc. selling numerous CBD Oil products at both wholesale and retail. Pursuant to the Share Exchange and Reorganization Agreement, the First Capital Venture Co. shareholders exchanged their shares which they held in First Capital Venture Holdings Co. for an aggregate total of 50,000 Class A preferred shares of the Company, wherein the shareholders would own 100% of this class of stock of the Company (the “Class A Preferred Shareholders”), which in the aggregate conferred voting control of the Company. First Capital Venture Co. became a wholly-owned subsidiary of the Company as result of the transaction.
 
Pursuant to a Stock Purchase Agreement dated June 8, 2017, the Company acquired all the capital stock of PotNetwork Media Group, Inc., a Nevada corporation (“PMG”), in exchange for 3,000,000 shares of the Company’s common stock issued to the shareholders of PMG, and the cancellation of a $50,000 promissory note between the Company and PMG. As a result, PMG became a wholly-owned subsidiary of the Company. PMG is the owner of the website www.potnetwork.com. Potnetwork.com is an informational website on the overall cannabis industry and does not market any products. PMG is also the publisher of the magazine, “PotNetwork .
 
The Company has two (2) wholly-owned subsidiaries:
 
 
·
First Capital Venture Co., a Florida corporation which has as its wholly-owned subsidiary, Diamond CBD, Inc., a Delaware corporation
 
·
PotNetwork Media Group, Inc., a Nevada corporation, operator of the website, PotNetwork.com.
 
Existing Products
 
The Company’s primary business is conducted through its subsidiary, First Capital Venture Co., whose subsidiary, Diamond CBD, Inc. (“Diamond CBD”) is engaged in the development and sales of hemp-derived CBD oil containing products. Generically, products containing hemp-derived CBD are sold as dietary supplements.
 
Hemp-derived CBD is distinguishable from CBD derived from marijuana. Hemp-derived CBD contains not more than 0.3 percent of THC, while marijuana contains in excess of this amount. Marijuana is regulated under the Controlled Substances Act. We do not believe that our hemp-derived CBD products are regulated under the Controlled Substances Act, but under the Agricultural Act of 2018, known as the “Farm Bill”.
 
The 2018 Farm Bill allows for the interstate sale and transfer of hemp-derived products for commercial or other purposes. It also puts no restrictions on the sale, transport, or possession of hemp-derived products, so long as those items are produced in a manner consistent with the law. The Farm Bill ensures that any cannabinoid-components of CBD -that is derived from hemp will be legal, if that hemp is produced in a manner consistent with the Farm Bill, associated federal regulations, associated state regulations, and by a licensed grower as defined in the Farm Bill.
 
The Company believes that all products produced and marketed by it, are in compliance with the Farm Bill and all other federal and state law and regulation.
 
Diamond CBD’s products are marketed under 15 brand names, including “Diamond CBD”, “Chill”, “Relax”, “MediPets” and the premium “Meds BioTech” label, as well as many others. In total, Diamond CBD offers over 800 products in variations by flavor, concentration and size that are sold over a nationwide distribution network of over 550 distributors and resellers that sell to thousands of brick-and-mortar retailers and online merchants. The overall product line, because of its size, is constantly in flux as new products are added and products are culled based on several factors including, but not limited to, consumer acceptance, inventory levels, and replacement as the result of incremental improvement.
 
 
23
 
 
While most of Diamond CBD’s products are geared to human health and wellness, its “MediPets” product line is a 100% natural and organic cannabinoid oil-based health and wellness solution for dogs and cats. Along with the company’s Pet CBD Food for small, medium, large dogs and cats, these products offer pet owners a new way to support their pet’s mood and wellness in a non-invasive, non-toxic way. The global pet care industry is expected to reach $110 billion in 2017, according to Euromonitor Research (The State Of Global Pet Care: Trends And Growth Opportunities, September 2017). Technavio, a leading market research firm, recently analyzed the global pet care industry and forecasted a CAGR of 5% between 2016-2020 (Global Pet Dietary Supplements Market 2018-2022
,
March 2018). According to that report, rising pet ownership combined with increased consumer spending on premium natural and organic pet care products are fundamental factors driving that growth.
 
Diamond CBD also offers for sale a majority of its products direct to consumers via its website, http://www.diamondcbd.com/.
 
Diamond DBD’s products are grouped in the following categories:
 
 
·
Flavored and unflavored CBD oils in varying concentrations
 
·
Vaping pens and additives
 
·
Edibles such as chewable “gummies”, crumble “dabs”, and other edible forms
 
·
Beverage energy/relaxation “shots”
 
·
CBD topical application creams in varying concentrations (including the premium “Meds BioTech” brand)
 
·
Pet (dog and cat) wellness products in various dosages and delivery formats (the “MediPets” brand)
 
Consumer markets served by Diamond CBD are extensive. In terms of geography, the products are sold wherever legal and the Company stipulates to its distribution channels that the products may only be sold to end-user persons eighteen years of age or older (See Item 1A “Risk Factors” for a further explanation of the laws regarding the sale of hemp-derived CBD products). Initially the Company focused distribution on market segments receptive to hemp-derived CBD products, such as vape shops and various countercultural focused retail outlets. Distribution was greatly expanded throughout 2017 and 2018 as the result of investment in new products and channel marketing (e.g., product catalogues and sell sheets, trade show and conference attendance, channel specific sales force), resulting in a vast broadening of distribution footprint and accelerated market growth, market penetration and revenue generation. For example, with the addition of specialized product lines, such as Meds BioTech and MediPets, the Company has been able to enter into new market segments such as vitamin/supplement shops, fitness centers, wellness practitioners of various disciplines, pet supply stores, and veterinary channels.
 
The strategic intent of the marketing plan in 2017 and 2018, has been to create a defendable “marketing wall” around distribution channels and retail outlets to keep competition out. The Company has spent over $11,000,000 in sales and marketing in 2017 and in 2018 combined. In parallel with distribution strategies, the Company has embraced various cause-related marketing initiatives in association with non-profit entities in order to position itself as socially conscious. Diamond CBD is engaged in select target market consumer awareness and brand preference campaigns, and is launching in 2019, two new national sales programs, one to educate and sell its products to consumers in shopping malls, and one to sell its products directly to brick-and-mortar resellers in metro markets in Florida via a fleet of mobile sales vans stocked with displays and product for immediate placement.
 
New Product Pipeline and Scientific Advisory Board
 
In July 2017, Diamond CBD initiated the formation of its “Scientific Advisory Board” which as of the date of this report is comprised of several physicians representing a variety of practice disciplines. The Scientific Advisory Board is charged with exploring the health and wellness benefits of hemp-derived CBD oil, its uses, and potential new applications. Costs incurred by the Scientific Advisory Board are reimbursed to the individual members on a monthly basis as they occur. The Company’s Chief Medical Officer, Richard Goulding, M.D., serves as Chairman of the Scientific Advisory Board.
 
The following are the biographies of current active members of the Scientific Advisory Board:
 
Dr. Richard E. Goulding, M.D., Chief Medical Officer, Chairman of the Scientific Advisory Board. Dr. Goulding was board certified by the American Board of Otolaryngology in 1985. Since 1984, he has maintained a private practice, and has served as the Chief of Otolaryngology, Holmes Regional Medical Center, Melbourne, Florida., attending Physician at: Humana Hospital, Sebastian, Deveraux Children’s Hospital, Melbourne, Sea Pines Rehabilitation Hospital, Palm Bay, Florida, Palm Bay Community Hospital, Palm Bay, Florida, and Holmes Regional Medical Center, Melbourne, Florida. Dr. Goulding is a member of: American Academy of Otolaryngology, American Academy of Facial Plastics & Reconstructive Surgery, Florida Society of Otolaryngology, American Medical Association and American Academy of Otolaryngic Allergy. Dr. Goulding graduated, with honors, in 1975 from the University of Florida and received his Doctor of Medicine in 1979 from Loyola University of Chicago.
 
 
24
 
 
Dr. Feldbaum is certified in vascular surgery by the American Board of Surgery. He completed a surgical residency at Montefiore Medical Center/Albert Einstein College of Medicine in New York City, as well as a vascular surgery fellowship at the Carolinas Heart Institute in North Carolina. Dr. Feldbaum is affiliated with the Memorial Healthcare System and the Westside Regional Medical Center both in Hollywood, Florida, and is also a member of the voluntary faculty clinical instructor of surgery at the University of Miami School of Medicine.
 
Each member of the Scientific Advisory Board has been issued 500,000 to 1,000,000 shares of restricted common stock of the Company for their participation and are paid in cash a per diem for attendance per meeting of the Scientific Advisory Board, plus any out-of-pocket expenses.
 
Product Formulation and Production
 
Diamond CBD uses its commercial suppliers and contract manufacturers for its product research and development, formulation, quality testing, production and packaging. These suppliers and manufacturers hold, as required, the necessary regulatory and other licenses/permits specific to each one’s activity. Diamond CBD outsources fulfillment as well. The Company has adopted a drop shipment fulfillment model that allows the third-party supplier to ship the merchandise directly to each customer. Therefore, we do not hold any inventory. Any and all raw materials constituting active ingredients in its products are routinely tested by a third-party laboratory for purity and consistency of active ingredient concentrations. The Company owns its own propriety formulas for all its products, which it regards as trade secrets (the Company does not own any patents nor has any pending), and continuously is engaged in both new product development and product incremental improvement with its suppliers. New product development and incremental improvement costs are absorbed by each respective supplier as part of their overhead in providing services to the Company.
 
Sales Channels
 
In addition to selling its products directly to consumers from its website, Diamond CBD, and indirectly the Company, depends upon its network of distributors and resellers to represent its product in various markets. The Company has over 500 distributors across the U.S. that distribute to thousands of points of retail distribution. No single distributor represents more than 10% of the Company’s aggregate sales volume. The Company is continuously evaluating the performance of its distributors and sales channels and periodically restructures or updates its agreements and methods of distribution.
 
The Markets for Our Products
 
Market research firm, Brightfield Group, estimates that the CBD oil industry is growing at a rate of 55% year over year and projects that the U.S. domestic market for CBD oil products will total a minimum of $1 billion by 2020 (Forbes, August 23, 2017).
 
The growth of the market shows that hemp-derived CBD products are becoming “mainstream” as consumers increasingly perceive them as providing wellness benefits.
 
Competition
 
Currently, in the United States, there are no businesses that can demonstrate or claim a dominant market share of the growing CBD products market. Competition, outside those companies that provide over .03 percent THC containing CBD in states where that is allowed under state law, is limited to numerous brands with geocentric distribution footprints. Overall, there are no major pharmaceutical manufacturing companies marketing general purpose CBD products into the overall CBD market at this time, although the Company is expecting such an entry in the future. Competition also includes many small regional marketers/packagers of CBD oil containing products that have limited distribution and economic resources.
 
 
25
 
 
Employees
 
The Company has 13 full-time employees.
 
Patents and Trademarks
 
The Company holds trademark, “PotNetwork”, under U.S. registration number 86860539, registered on January 31, 2017, and expiring on January 31, 2027. It is used by the Company in its own branding and that of its website, PotNetwork.com.
 
The Company holds no patents, nor at this time, has any patent pending.
 
Government Regulation
 
I. The Company’s CBD Products Are Not Subject to the Controlled Substances Act
 
The Agriculture Improvement Act of 2018 (“AIA” or “the Act”) exempted hemp-derived cannabidiol products (“hemp-derived CBD products”) from the federal Controlled Substances Act (“CSA”). Specifically, the AIA, also known as the Farm Bill of 2018, established a legal definition of “hemp”: the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol [∆-9 THC] concentration of not more than 0.3 percent on a dry weight basis.
 
The Act amends the CSA to exclude “hemp” from the definition of “marihuana.” It also amended the CSA to exclude THC found in “hemp” from the “tetrahydrocannabinols” listed in Schedule I. Therefore, hemp-derived CBD products that contain less than less than 0.3% of 9∆-THC, such as those marketed by PotNetwork, are not controlled substances under the CSA. These amendments to the CSA took immediate effect on December 20, 2018.
 
By way of background, the CSA establishes five “schedules” into which a substance with abuse potential may be classified. Substances that fall under any one of the five schedules are subject to various requirements and restrictions enforced by the U.S. Drug Enforcement Administration (“DEA”). The most restrictive is Schedule I, which is reserved for those substances having a high potential for abuse that do not have a currently accepted medical use, and that lack accepted safety for use under medical supervision.
 
Marijuana has long been classified under Schedule I. Previously, DEA took the position that CBD met the expansive definition of “marijuana”, which made it subject to Schedule I as well. Specifically, DEA created a code number in Schedule I for “marihuana extract,” defined as “an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant.” DEA made clear that the agency considered CBD to fall within the definition of “marihuana extract” (and to therefore be a Schedule I substance) if the CBD came from the part of the cannabis plant that is included within the definition of “marijuana.”
 
The passage of the AIA confirms that hemp-derived CBD products are now excluded from the CSA. As noted above, the AIA amended the definition of “marihuana” as follows:
 
(A) Subject to subparagraph (B), the term ‘marihuana’ means all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds to resin.
 
(B) The term ‘marihuana’ does not include-
 
(i) hemp, as defined in section 297A of the Agricultural Marketing Act of 1946.
 
 
26
 
 
II. Limits of the AIA
 
Although the AIA removed “hemp” from the CSA, the Act has limitations.
 
a. Products containing more than 0.3% of 9∆-THC still subject to the CSA.
 
Notably, the AIA’s exclusion of “hemp” from the CSA definition of “marihuana” is limited to those parts, derivatives, or extracts of the plant containing less than 0.3% of 9∆-THC. Parts, derivatives, and extracts containing levels of 9∆-THC greater than 0.3% meet the definition of marihuana and are subject to the CSA. Consequently, manufacturers and distributors of CBD products must be prudent with respect to verifying the levels of 9∆-THC in products.
 
b. Hemp production and cultivation restrictions
 
The AIA requires the establishment of a shared Federal-state program to regulate the cultivation and production of hemp. The USDA is actively engaged in rulemaking efforts to implement these requirements and state laws are evolving in response. Our Company is not involved in the cultivation or production of hemp; however, we recognize that new rules will impact the industry as a whole and we are closely monitoring the USDA’s rulemaking efforts.
 
c. Hemp-derived CBD remains subject to FDA regulatory authority
 
Further, The Federal Food, Drug and Cosmetic Act (“FDCA”) and the AIA authorize the FDA to regulate the marketing and distribution of hemp products in interstate commerce that are intended for consumption, including topical use. Pursuant to its jurisdiction, FDA may regulate hemp as a feed, food, dietary supplement, cosmetic or drug depending on the intended use of the hemp and whether the hemp is otherwise a permissible ingredient for a particular intended use. The AIA expressly preserves the FDA’s authority over “hemp” that is intended to be used as a drug, device, cosmetic, food (including animal food), dietary supplement, or tobacco product.
 
Generally, hemp-derived CBD products that are intended for ingestion and intended to support the normal function/structure of the body or added as an ingredient in food, may be considered a dietary supplement or conventional food under the FDCA. However, FDA has taken the position through advisory Warning Letters that CBD products are precluded from being marketed as dietary supplements or as food because CBD is subject to statutory exclusions designed to protect the integrity of the drug approval process.
 
Specifically, the statutory definition of a “dietary supplement” excludes an “article” that has been approved as a drug under section 505 of the FDCA. The term “dietary supplement” also excludes “an article” if (1) it has been authorized for investigation as a new drug; (2) substantial clinical investigations have been instituted on the article and their existence made public; and (3) it was not marketed as a food or dietary supplement prior to being authorized for investigation as a new drug. For purposes of this exclusion, the FDA has interpreted “authorized for investigation as a new drug” to mean that an Investigational New Drug application (“IND”) has been submitted for the active ingredient or active moiety.
 
FDA has taken the position that hemp-derived CBD cannot be marketed as dietary supplement because a CBD isolate has been approved as a drug, Epidiolex, and prior to approval, was subject to substantial clinical investigations under an IND. Further, FDA has stated that it has not been provided with the evidence needed to overcome this exclusion. The FDA asserts this same position with regard to products marketed as food under a separate, but identical, statutory provision applicable to “food” broadly. As such, FDA takes the position that hemp-derived CBD products intended for ingestion may be adulterated.
 
That being said, FDA has yet to take enforcement action against CBD products and has initiated a regulatory process to determine whether there is a regulatory pathway to permit the marketing of these products. Indeed, FDA in recognizing the significant increase in hemp-derived CBD products on the market, the Agency held a public meeting on May 31, 2019 requesting scientific information and data regarding the safety, manufacturing, product quality, marketing, labeling, and sale of products containing hemp-derived CBD. It further requested that comments be filed with the agency by July 2, 2019. This meeting and request for comments signaled FDA’s intent to consider various regulatory options for CBD products, including but not limited to (1) requiring companies to seek approval to market such product; (2) issuing regulations setting forth the conditions which such products may be marketed in food and dietary supplements; or (3) prohibiting the use of hemp-derived CBD in foods and dietary supplements. With that said, there is significant regulatory uncertainty around this category which makes it difficult to predict the likely outcome of this process FDA has initiated.
 
 
27
 
 
d. Hemp-derived CBD products are subject to regulation on the state level.
 
Although the AIA provided clarity regarding the status of hemp-derived CBD under the federal CSA, the AIA did not address the myriad of state laws and regulations governing such products. For example, hemp-derived CBD still meets the definition of a controlled substance under certain laws.
 
FDA Warning Letter
 
PotNetwork Holdings received a Warning Letter from the U.S. Food and Drug Administration on March 28, 2019 related to the marketing of CBD products by Diamond CBD, a subsidiary of the Company.
 
First, FDA alleged that some claims made by Diamond CBD on its website established that the products were unapproved new drugs. Specifically, FDA stated that the claims suggested that the products were intended to cure, mitigate, treat, or prevent disease, the definition of a drug under section 201(g)(1)(B) of the FDCA. These claims included references to clinical studies on CBD demonstrating health benefits for patients with certain diseases, including Alzheimer’s and diabetes. Based on these claims, the FDA considered the products to be unapproved new drugs in violation of the FDCA.
 
Next, FDA alleged that the products cannot lawfully be marketed as a dietary supplement because the Agency has concluded that CBD is excluded from the definition of a dietary supplement. Specifically, the section 201(ff)(3)(B)(i) and (ii) of the FDCA excludes from the definition of “dietary supplement” articles that are active ingredients in drugs or for which substantial investigations as a drug have commenced if the substances were not marketed as food or dietary supplements prior to the approval of the drug or commencement of the investigation. CBD isolate is the active ingredient in the approved drug, Epidiolex, and substantial clinical investigations have been conducted under IND. FDA has taken the position that there is no evidence that CBD was marketed as a food and dietary supplement prior to the approval or investigation of these drugs and, therefore, the hemp-derived CBD products do not meet the definition of a dietary supplement. Consequently, such products may violate the FDCA.
 
Finally, 301(ll) of the FDCA prohibits food from containing an approved drug or drug for which substantial clinical investigations have been instituted unless such drug was marketed as food prior to the approval of the drug or institution of the clinical investigation. As discussed, FDA has taken the position that there is no evidence that CBD was not marketed as food prior to substantial clinical investigations on CBD conducted under IND were made public. The Warning Letter states that the Diamond CBD products containing a Nutrition Facts panel are not appropriately marketed because the presence of CBD excludes the product from being marketed as a food. Consequently, such products may violate the FDCA.
 
PotNetwork has taken significant steps to respond to FDA concerns enumerated in the March 28, 2019 Warning Letter. Diamond CBD has removed all claims from the website that are referenced in the Warning Letter has suggesting that the hemp-derived CBD products are intended to be used as a drug. PotNetwork also retained Venable LLP to serve as regulatory counsel. At counsel’s instruction, Diamond CBD has also removed other claims in an effort to ensure compliance with the FDCA and be responsive to FDA’s concerns.
 
Additionally, counsel provided a written response to the Warning Letter on April 30, 2019 identifying the changes implemented by Diamond CBD and responding to the allegations related to CBD prohibition in a dietary supplement. As of date of this filing, PotNetwork has not received a response from the Agency. Nor has it been the subject of any other enforcement action.
 
Importantly, the Letter did not state or imply any consumer or other complaint relating to any of Company’s products in terms of their purity, quality, or safety.
 
 
28
 
 
 
Our directors hold office until the next annual general meeting of the stockholders or until their successors are elected and qualified. Our officers are appointed by our Board of Directors and hold office until the earlier of their death, retirement, resignation, or removal.
 
The following table sets forth the names and ages of the members of our Board of Directors and our executive officers and the positions held by each.
 
Name
 
Age
 
Title
Gary Blum
 
79
 
Director
Kevin Hagen
 
50
 
CEO/Director
Murugan Venkat
 
66
 
CFO
 
Gary L. Blum, 79, has been the Chairman of PotNetwork Holdings, Inc. since November 2015 and was its Chief Executive Officer from November 2015 until September 2017. Mr. Blum is also a practicing attorney since 1979 with the Law Offices of Gary L. Blum where his focus is advising a variety of closely held private companies as well as public companies in business, corporate, securities and entertainment law. Mr. Blum has served as a director of Rennova Health, Inc. since October 2017, and, from September 2009 until July 2017, served as the Chairman and CEO of Thunderclap Entertainment, Inc. Mr. Blum received his B.S., Magna Cum Laude, in Mathematics from Loras College in 1962; M.A. in Philosophy from the University of Notre Dame in 1966; and his J.D. and M.B.A. degrees from the University of Southern California Gould School of Law and Marshall School of Business, respectively, in 1978. He has been a member of the California State Bar since 1979.
 
Kevin Hagen, 50, has been the Chief Executive Officer of PotNetwork Holdings, Inc. since October 25, 2018, and previously since its inception has been the President of First Capital Venture Co., the parent of Diamond CBD, Inc. Mr. Hagen is a practicing attorney with Hagen & Hagen Law Firm with over 22 years of experience. He is also a member of the Florida Bar Association. He completed his BS from University of Florida and JD from Nova Southeastern University.
 
Murugan Venkat, 66, Ph.D., FCA, was appointed Chief Financial Officer of PotNetwork Holdings, Inc. effective June 10, 2018. Dr. Venkat received his Ph. D. in corporate finance from the University of Madras in India. He is a chartered accountant in India. He began his career as an Associate Professor at IFMR, Chennai. Before moving to United States, his past experiences include (a) 9 years in the public sector undertaking as FA&CAO (Financial Advisor and Chief Accounts Officer); (b) 3 years as the Chief Accountant in a sugar factory; and (c) 3 years as the Controller in a private airline. In South Florida, he worked as the corporate controller for 10 years in a manufacturing company. Since 2018, he is the corporate controller for JMJ Group, Dallas, TX.
 
Family Relationships
 
There are no familial relationships among any of our officers or directors. None of our directors or officers is a director in any other reporting companies except as disclosed. The Company is not aware of any proceedings to which any of the Company‚ officers or directors, or any associate of any such officer or director, is a party adverse to the Company or any of the Company subsidiaries or has a material interest adverse to it or any of its subsidiaries.
 
Board Committees
 
There are currently no committees of the Board of Directors.
 
Code of Ethics
 
Our board of directors intends to adopt a code of ethics that our officers, directors and any person who may perform similar functions will be subject to.
 
 
29
 
 
Involvement in Certain Legal Proceedings
 
To our knowledge, our directors and executive officers have not been involved in any of the following events during the past ten years:
 
 
1.
any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
 
2.
any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
 
3.
being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities;
 
4.
being found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures Trading Commission to have violated a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
 
5.
being subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
 
6.
being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.
 
 
The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our chief executive officer for services rendered in all capacities for the periods set forth below.
 
Summary Compensation Table
 
 
Nonqualified
 
Non-Equity
 
Deferred
 
Name and
 
Stock
 
Option
 
Incentive Plan
 
Compensation
 
All Other
 
Principal
 
Bonus
 
Awards
 
Awards
 
Compensation
 
Earnings
 
Compensation
 
Total
 
Position
 
Year
 
Salary
 
($)
 
($)
 
($)
 
($)
 
($)
 
($)
 
($)
 
 
Kevin Hagen
 
2019
 
-0-
-0-
-0-
-0-
-0-
-0-
-0-
-0-
 
 
2018
 
 
-0-
 
 
 
-0-
 
 
 
-0-
 
 
 
-0-
 
 
 
-0-
 
 
 
-0-
 
 
 
-0-
 
 
 
-0-
 
   
 
Richard Goulding
2018
 
49,000
 
-0-
-0-
-0-
-0-
-0-
-0-
 
49,000
 
Former CEO(1)
2017
 
16,000
(2)
 
-0-
-0-
-0-
-0-
-0-
-0-
 
16,000
(2)
 
2016
 
-0-
 
-0-
-0-
-0-
-0-
-0-
-0-
 
-0-
     
 
 
Gary Blum
 
2018
 
-0-
 
-0-
 
170,000
 
-0-
-0-
-0-
-0-
170,000
 
Director
 
2017
 
-0-
 
-0-
 
-0-
 
-0-
-0-
-0-
-0-
-0-
 
2016
 
-0-
 
-0-
 
-0-
 
-0-
-0-
-0-
-0-
-0-
___________ 
(1)
Richard Goulding, M.D., resigned as CEO on October 25, 2018 and was replaced by Kevin Hagen, Esq.
(2)
Represents accrued salary attributed to that period in the employment agreement with Dr. Goulding entered into in July 2018.
 
 
30
 
 
Employment Agreements
 
The Company entered into an employment agreement with Richard Goulding, M.D., prior CEO, on July 9, 2018 retroactive to September 5, 2017, for a period of one year. He was not engaged by the Company prior to that date. Under the terms of the agreement, Dr. Goulding received a base salary, received a initial common stock grant and common stock options. The agreement was expired and was not renewed.
 
The Company does not have any employment agreements with any of our officers and directors, all of whom have performed services on our behalf for no compensation, including Kevin Hagen, Esq. CEO, and Murugan Venkat, CFO.
 
Compensation of Directors
 
Gary Blum, Chairman, was issued 2,000,000 shares of restricted common stock in 2019 in recognition of services performed in prior years as sole director of the Company. Kevin Hagen receives no compensation for being a member of the Board of Directors.
 
 
Related Party Transactions
 
We maintain our offices at 3531 Griffin Road, Fort Lauderdale, FL 33312. The space is provided to the Company at no cost by Kevin Hagen, our CEO and president of our wholly owned subsidiary First Capital Venture Co.
 
 
As of September 30, 2019, we had 700,706,621 common shares outstanding. The following table sets forth certain information regarding our shares of common stock beneficially owned as of September 30, 2019, for (i) each stockholder known to be the beneficial owner of five percent (5%) or more of our outstanding shares of common stock, (ii) each named executive officer and director, and (iii) all executive officers and directors as a group. A person is considered to beneficially own any shares: (i) over which such person, directly or indirectly, exercises sole or shared voting or investment power, or (ii) of which such person has the right to acquire beneficial ownership at any time within sixty (60) days through an exercise of stock options or warrants or otherwise. Unless otherwise indicated, voting and investment power relating to the shares shown in the table for our directors and executive officers is exercised solely by the beneficial owner or shared by the owner and the owner’s spouse or children.
 
 
31
 
 
For purposes of this table, a person or group of persons is deemed to have “beneficial ownership” of any shares of common stock that such person has the right to acquire within sixty (60) days of the date of this Form 10. For purposes of computing the percentage of outstanding shares of our common stock held by each person or group of persons named above, any shares that such person or persons has the right to acquire within sixty (60) days of the Closing Date is deemed to be outstanding but is not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership.
 
AMOUNT AND NATURE OF BENEFICIAL OWNERSHIP
 
Common Stock
Name and Address of Beneficial Owner
(2)
 
Direct
 
Indirect
 
Total
 
Percentage
of Class (1)
 
Executive Officers and Directors
 
Gary Blum
 
2,000,000
 
-0-
 
2,000,000
 
.29
%
Kevin Hagen
 
27,750,000
 
-0-
 
27,750,000
 
3.96
%
Murugan Venkat
 
-0-
 
-0-
 
-0-
 
-0-
%
Officers and Directors as a Group
 
29,750,000
 
-0-
 
29,750,000
 
4.25
%
 
Other 5% Holders
(3)
 
Elinor Taieb
 
64,651,438
 
-0-
 
64,651,438
 
9.23
%
 
Class A Preferred Stock
(4)
 
Direct
 
Indirect
 
Total
 
Percentage
of Class
 
Kevin Hagen
 
20,742
 
-0-
 
20,742
 
60.4
%
Elinor Taieb
 
13,547
 
-0-
 
13,597
 
39.5
%
____________ 
(1)
Based on a total of issued and outstanding shares as of September 30, 2019 of 700,836,384.
(2)
The address of each officer is 3531 Griffin Road, Fort Lauderdale, FL 33312
(3)
Pursuant to the Convertible Notes that the Company has with Iliad Research, the Company is prohibited from issuing shares to Iliad Research if such issuance would cause Iliad Research to own more than 4.99% of the number of common shares of the Company outstanding at the time of such issuance. Thus, while Iliad Research may convert into an aggregate of 223,000,000 shares, it may not own more than 4.99% of the common shares of the Company at any one time and is therefore not included in the ownership table. Ownership is determined in accordance with Section 13(d) of the Securities Exchange Act of 1934.
(4)
Each share of Class A preferred stock is convertible into 0.01% of the total number of shares of Common Stock outstanding at the Conversion Time. On any matter presented to the shareholders of the Corporation for their action or consideration at any meeting of shareholders of the Corporation (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of Series A Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series A Preferred Stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Articles of Incorporation, holders of Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.
 
Based on the preceding and upon a total quantity of issued and outstanding shares as of September 30, 2019 of 700,836,384, each share of Class A preferred stock is convertible into 70,084 shares of common stock. As a result, if each of the two Class A preferred shareholders listed were able to convert 100% of each’s Class A preferred stock, Kevin Hagen, who holds 20,742 Class A preferred shares, would receive 1,453,682,328 shares of common stock; and Elinor Taieb, who holds 13,547 Class A preferred shares, would receive 949, 427,948 shares of common stock.
 
 
32
 
 
 
This prospectus relates in part to our registering the resale of 223,000,000 shares of common stock of the Company by the Selling Stockholder who may acquire such shares upon the conversion of the Notes. There can be no assurance that the Selling Stockholder will sell any or all of their common stock offered by this prospectus. We do not know if, when, or in what amounts, the selling stockholder may offer the common stock for sale.
 
Selling Stockholders
 
The following table sets forth:
 
 
·
the names of the Selling Stockholder;
 
·
the number of shares of common stock that can be acquired by the Selling Stockholder through the conversion of the Notes;
 
·
the number of shares of common stock being registered with respect to the Selling Stockholder;
 
·
the number of shares of common stock owned by the Selling Stockholders after the offering assuming all shares acquired by the Selling Shareholder are sold; and
 
·
the person with voting or investment control if the stockholder is not a natural person.
 
As of January 17, 2020 there were 700,706,621, shares of common stock outstanding. To the extent that any successor(s) to the named selling Stockholder wish to sell under this prospectus, we will file a prospectus supplement identifying such successors as selling stockholders.
 
Selling Stockholder
 
Shares
Acquirable
upon
Conversion of
Note
 
Shares Being Registered
 
Shares Owned
After the
Offering
Assuming all
Note
Principal,
Interest and
Fees are
Converted and
all Shares Sold
 
Person with Voting or Investment Control
 
Iliad Research & Trading, L.P.(1)
 
223,000,000
 
223,000,000
 
0
 
John M. Fife
  
(1)
Pursuant to the Convertible Notes that the Company has with Iliad Research, the Company is prohibited from issuing shares to Iliad Research if such issuance would cause Iliad Research to own more than 4.99% of the number of common shares of the Company outstanding at the time of such issuance. Thus, while Iliad Research may convert into an aggregate of 223,000,000 shares, it may not own more than 4.99% of the common shares of the Company at any one time. Ownership is determined in accordance with Section 13(d) of the Securities Exchange Act of 1934.
 
 
33
 
 
PLAN OF DISTRIBUTION
 
We are registering 223,000,000 shares of Common Stock for sale at the price of $.02 per share.
 
Sales by Selling Stockholder
 
The Selling Stockholder (the “Selling Stockholder”) of the common stock (“Common Stock”) of the Company and any of their pledges, assignees and successors-in-interest may, from time to time, sell any or all of their shares of Common Stock at a fixed price of $.02 per share on any stock exchange, market or trading facility on which the shares are traded or in private transactions. The common shares are currently listed on OTC Markets under the symbol POTN. The Selling Stockholder may use any one or more of the following methods when selling shares:
  
 
·
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
 
·
block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
 
·
purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
 
·
an exchange distribution in accordance with the rules of the applicable exchange;
 
·
privately negotiated transactions;
 
·
settlement of short sales entered into after the date of this prospectus;
 
·
broker-dealers may agree with the Selling Stockholder to sell a specified number of such shares at a stipulated price per share;
 
·
a combination of any such methods of sale;
 
·
through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; or
 
·
any other method permitted pursuant to applicable law.
 
The Selling Stockholder may also sell shares under Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), if available, rather than under this prospectus.
 
Broker-dealers engaged by the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission or a principal transaction a markup or markdown in compliance with FINRA Rule 2121.
 
In connection with the sale of the Common Stock or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Common Stock in the course of hedging the positions they assume. “Short sale” is the name given to a transaction that takes place when a person believes a company’s stock price is about to go down. The person borrows from his broker or other individual shares of the company’s stock and sells the borrowed shares at the current price. After the price goes down, the person buys in the market, shares of the company’s stock at the reduced price and uses the purchased shares to replace the shares that were borrowed. As a result of the short sale, the person succeeds in buying low and selling high. The buying and selling are simply reversed in order. Short sales can have the effect of driving down the trading price of a company’s stock. If a stock price is falling and stockholders are selling short, stock purchases for the purpose of replacing borrowed shares further depress the market and encourages additional short selling. The net effect can be a downward spiral of the stock price of the company.
 
 
34
 
 
The Selling Stockholder may also sell shares of the Common Stock short and deliver these securities to close out their short positions, or loan or pledge the Common Stock to broker-dealers that in turn may sell these securities. The Selling Stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
 
The Selling Stockholder and any broker dealers or agents that are involved in selling the shares may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.
 
The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the shares. The Company has agreed to indemnify the Selling Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
 
Because the Selling Stockholder may be deemed to be an “underwriter” within the meaning of the Securities Act, he will be subject to the prospectus delivery requirements of the Securities Act. In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than under this prospectus. It is our understanding that the Selling Stockholder has not entered into any written or oral agreements, understandings or arrangements with any underwriter or broker-dealer regarding the sale or the resale shares. There is no underwriter or coordinating broker acting in connection with the proposed sale of the resale shares by the Selling Stockholder.
 
We agreed to keep this prospectus effective until the earlier of (i) the date on which the shares may be resold by the Selling Stockholder without registration and without regard to any volume limitations by reason of Rule 144(e) under the Securities Act or any other rule of similar effect or (ii) all of the shares have been sold pursuant to the prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale shares will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale shares may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.
 
Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale shares may not simultaneously engage in market making activities with respect to the Common Stock for a period of two business days prior to the commencement of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of shares of the Common Stock by the Selling Stockholder or any other person. We will make copies of this prospectus available to the Selling Stockholder and have informed him of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale.
 
 
The Company is authorized to issue up to 1,500,000,000 shares of common stock, $0.00001 par value. As of January 17, 2020, we had outstanding 700,706,621 shares of common stock. The holders of our Common Stock are entitled to one vote per share held and have the sole right and power to vote on all matters on which a vote of stockholders is taken. Voting rights are non-cumulative. Common stockholders are entitled to receive dividends when, as, and if declared by the Board of Directors, out of funds legally available therefore and to share pro rata in any distribution to stockholders. Upon liquidation, dissolution, or the winding up of our Company, common stockholders are entitled to receive the net assets of our Company in proportion to the respective number of shares held by them after payment of liabilities which may be outstanding. The holders of common stock do not have any preemptive right to subscribe for or purchase any shares of any class of stock of the Company. The outstanding shares of common stock will not be subject to further call or redemption and are fully paid and non-assessable. To the extent that additional common shares are issued, the relative interest of existing stockholders will likely be diluted.
 
 
35
 
 
Our Articles of Incorporation authorize the issuance by resolution of our Board of Directors of up to 50,000 shares of Class A preferred stock. As of June 30, 2019, we had 34,289 shares of Class A Preferred Stock issued and outstanding. Each share of Class A preferred stock is convertible into 0.01% of the total number of shares of Common Stock outstanding at the Conversion Time. On any matter presented to the shareholders of the Corporation for their action or consideration at any meeting of shareholders of the Corporation (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of Series A Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series A Preferred Stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Articles of Incorporation, holders of Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.
 
DESCRIPTION OF NOTE RELATED TO SHARES BEING REGISTERED
 
We are registering 223,000,000 common shares to be issued upon the conversion of two Notes and resale by the Selling Stockholder. The material terms of each Note overlying the Note Shares being registered, as well as the material terms of the transaction in which we issued the Notes is summarized below.
 
Description of Note 1
 
Number of shares issuable on conversion
 
Conversion
price ($)
 
Material
Terms
 
Notes in the principal face amount of $5.525 million
 
138,825,352
 
See below (1)
 
See below (1)
 
(1) On October 25, 2018, the Company issued a Note in the face amount of $5,525,000 which accrues interest at the rate of 10% per annum. The note has an Original Issue Discount (OID) of $500,000. The Note and any interest thereon is convertible at a fixed rate of $0.45 per share of common stock or after 12 months, at a variable conversion rate, the “redemption conversion price” at the lower of the fixed rate of $.45 per share, or a discount to the market price as defined in the Note. The Note is comprised of five (5) tranches (each, a “Tranche”), consisting of (i) an Initial Tranche in an amount equal to $1,400,000.00 and any interest, costs, fees or charges accrued thereon or added thereto under the terms of this Note and the other Transaction Documents (as defined in the Purchase Agreement) (the ‘‘Initial Tranche”), and (ii) four (4) additional Tranches, one (l) in the amount of $1,375,000.00, one (l) in the amount of $550,000.00, and two (2) in the amount of $1,100,000.00, plus any interest, costs, fees or charges accrued thereon or added thereto under the terms of this Note and the other Transaction Documents. This summary does not purport to be complete and is qualified in its entirety by the Note as attached hereto as Exhibit 10.4.
 
Description of Note 2
 
Number of shares issuable on conversion
 
Conversion
price ($)
 
Material
Terms
 
Notes in the principal face amount of $3.325 million
 
84,174,648
 
See below (2)
 
See below (2)
 
(2) On February 8, 2019, the Company issued a Note in the face amount of $3,325,000 which accrues interest at the rate of 10% per annum. The note has an Original Issue Discount (OID) of $300,000. The Note and any interest thereon is convertible at a fixed rate of $0.45 per share of common stock or after 12 months, at a variable conversion rate, the “redemption conversion price” at the lower of the fixed rate of $.45 per share, or a discount to the market price as defined in the Note.. The Note is comprised of three (3) tranches (each, a “Tranche”), consisting of (i) an initial Tranche in an amount equal to $1,125,000.00 and any interest, costs, fees or charges accrued thereon or added thereto under the terms of this Note and the other Transaction Documents (as defined in the Purchase Agreement) (the ‘‘Initial Tranche”), and (ii) two (2) additional Tranches, one (l) in the amount of $550,000.00 and one (1) in the amount of $1,650,000.00, plus any interest, costs, fees or charges accrued thereon or added thereto under the terms of this Note and the other Transaction Documents. This summary does not purport to be complete and is qualified in its entirety by the Note as attached hereto as Exhibit 10.6.
 
 
36
 
 
INTERESTS OF NAMED EXPERTS AND COUNSEL
 
No experts or counsel to the Company have been hired on a contingent basis and none of them will receive a direct or indirect interest in the Company.
 
 
The financial statements of PotNetwork Holdings, Inc. for the fiscal year ended December 31, 2018 have been audited by Yusufali & Associates, LLC, an independent registered public accounting firm as set forth in its report and are included in reliance upon such report given on the authority of such firm as experts in accounting.
 
The financial statements of PotNetwork Holdings, Inc. for the fiscal year ended December 31, 2017 have been audited by Manohar Chowdhry & Associates, an independent registered public accounting firm as set forth in its report and are included in reliance upon such report given on the authority of such firm as experts in accounting.
 
 
Jonathan D. Leinwand, P.A., Aventura, Florida, will pass upon the validity of the shares of our common stock to be sold in this offering.
 
 
We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities we are offering to sell. This prospectus, which constitutes part of the registration statement, does not include all of the information contained in the registration statement and the exhibits, schedules and amendments to the registration statement. For further information with respect to us and our securities, we refer you to the registration statement and to the exhibits and schedules to the registration statement. Statements contained in this prospectus about the contents of any contract, agreement or other document are not necessarily complete, and, in each instance, we refer you to the copy of the contract, agreement or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference.
 
You may read and copy the registration statement of which this prospectus is a part at the SEC’s public reference room, which is located at 100 F Street, N.E., Room 1580, Washington, DC 20549. You can request copies of the registration statement by writing to the Securities and Exchange Commission and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the SEC’s public reference room. In addition, the SEC maintains a website, which is located at www.sec.gov, that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. You may access the registration statement of which this prospectus is a part at the SEC’s website.
 
As of July 9, 2019, we became subject to the information reporting requirements of the Securities Exchange Act of 1934, and we will file reports, proxy statements and other information with the SEC. All documents filed with the SEC are available for inspection and copying at the public reference room and website of the SEC referred to above. We maintain a website at www. potnetworkholding.com. You may access our reports, proxy statements and other information free of charge at this website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information on such website is not incorporated by reference and is not a part of this prospectus.
 
 
37
 
 
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018
   
 
 
F-1
 
 
BALANCE SHEET - Unaudited
 
 
 
September 30,
2019
 
 
December 31,
2018
 
Assets
 
 
 
 
 
 
Current Assets
 
 
 
 
 
 
Cash/Bank Balances
 
$ 68,476
 
 
$ 584,426
 
Accounts Receivable
 
 
 
 
 
 
 
 
From Customers
 
$ 63,414
 
 
$ 119,274
 
From related parties
 
 
 
 
 
$ -
 
From others
 
$ 500,000
 
 
$ -
 
Total Accounts Receivable
 
$ 563,414
 
 
$ 119,274
 
Advances - Drop Shipper
 
$ 4,876,880
 
 
$ 4,289,928
 
Prepaid Expenses
 
$ 823,801
 
 
$ 220,902
 
Total Current assets
 
$ 6,332,571
 
 
$ 5,214,530
 
TOTAL ASSETS
 
$ 6,332,571
 
 
$ 5,214,530
 
Liabilities
 
 
 
 
 
 
 
 
Current Liabilities
 
 
 
 
 
 
 
 
Payables
 
$ 171,008
 
 
$ 469,821
 
Current portion of Notes Payable, convertible
 
$ 248,002
 
 
$ 306,150
 
Total Current Liabilities
 
$ 419,010
 
 
$ 775,971
 
Long-term Liabilities
 
 
 
 
 
 
 
 
Loan from 3rd Party with interest
 
$ 40,320
 
 
$ 38,400
 
Notes Payable
 
$ 4,728,906
 
 
$ 3,267,824
 
Total long-term liabilities
 
$ 4,769,226
 
 
$ 3,306,224
 
Total Liabilities
 
$ 5,188,236
 
 
$ 4,082,195
 
Stockholders' Equity
 
 
 
 
 
 
 
 
Common: Authorized 1,000,000,000 shares, $.00001 par value; and 700,836,384 Issued and outstanding as of September 30, 2019 and 569,364,762 shares issued and outstanding as of December 31, 2018
 
$ 3,565,065
 
 
$ 3,169,040
 
Preferred Stock Class A Authorized - 50,000 shares, $.00001 Par value; and 34,289 Issued and outstanding, as of September 30, 2019 and 39,839 issued and outstanding as of December 31, 2018
 
$ 400
 
 
$ 400
 
Retained Earnings
 
$ (2,421,130 )
 
$ (2,037,105 )
Total Stockholders' Equity
 
$ 1,144,335
 
 
$ 1,132,335
 
Total Liabilities & Equity
 
$ 6,332,571
 
 
$ 5,214,530
 
 
The accompanying notes are an integral part of these financial statements.
 
 
F-2
 
   
INCOME STATEMENT (Unaudited)
 
 
3 months ended
 
 
9 months ended
 
 
 
September 30,
2019
 
 
September 30,
2018
 
 
September 30,
2019
 
 
September 30,
2018
 
Revenue
 
 
 
 
 
 
 
 
 
 
 
 
Sales
 
$ 3,629,621
 
 
$ 5,923,161
 
 
$ 14,157,742
 
 
$ 17,967,189
 
Cost of goods sold
 
$ 2,181,802
 
 
$ 2,969,227
 
 
$ 8,557,686
 
 
$ 10,272,081
 
Gross profit
 
$ 1,447,819
 
 
$ 2,953,934
 
 
$ 5,600,056
 
 
$ 7,695,108
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operating expenses
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
$ -
 
 
$ -
 
 
$ -
 
 
$ -
 
Sales & Marketing
 
$ 1,695,562
 
 
$ 2,551,862
 
 
$ 5,108,343
 
 
$ 6,615,125
 
General & Administrative Expenses
 
$ 172,461
 
 
$ 356,532
 
 
$ 627,756
 
 
$ 709,887
 
Total operating expenses
 
$ 1,868,023
 
 
$ 2,908,394
 
 
$ 5,736,099
 
 
$ 7,325,012
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financing expenses
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest Exp
 
$ 84,764
 
 
$ 4,220
 
 
$ 247,982
 
 
$ 12,133
 
Total financing expenses
 
$ 84,764
 
 
$ 4,220
 
 
$ 247,982
 
 
$ 12,133
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Expenses
 
$ 1,952,787
 
 
$ 2,912,614
 
 
$ 5,984,081
 
 
$ 7,337,145
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Profit (Loss) before Income Tax
 
$ (504,968 )
 
$ 41,320
 
 
$ (384,025 )
 
$ 357,963
 
Provision for Income Tax
 
$ -
 
 
$ -
 
 
$ -
 
 
$ -
 
Net Profit (Loss)
 
$ (504,968 )
 
$ 41,320
 
 
$ (384,025 )
 
$ 357,963
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Earnings per share
 
$ (0.000721 )
 
$ 0.000092
 
 
$ (0.000548 )
 
$ 0.000797
 
Basic and diluted
 
$ (0.000721 )
 
$ 0.000092
 
 
$ (0.000548 )
 
$ 0.000797
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted weighted average common shares outstanding
 
 
700,836,384
 
 
 
448,921,254
 
 
 
700,836,384
 
 
 
448,921,254
 
 
The accompanying notes are an integral part of these financial statements.
 
 
F-3
 
  
CASH FLOW STATEMENT
 
 
 
3 months ended
 
 
9 months ended
 
 
 
30-Sep-19
 
 
30-Sep-18
 
 
30-Sep-19
 
 
30-Sep-18
 
Net Income (Loss)
 
$ (504,968 )
 
$ 41,320
 
 
$ (384,025 )
 
$ 357,963
 
Adjustments to reconcile net income (loss)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accounts Receivable from customers
 
$ 43,847
 
 
$ (19,879 )
 
$ 55,860
 
 
$ (119,274 )
Accounts Receivable from others
 
$ (500,000 )
 
$ 395,331
 
 
$ (500,000 )
 
$ (395,331 )
Other Assets
 
$ 570,695
 
 
$ (271,405 )
 
$ (1,189,851 )
 
$ (4,510,830 )
Payable
 
$ 75,683
 
 
$ (233,610 )
 
$ (356,961 )
 
$ (251,766 )
Total Adjustments to reconcile net income (loss)
 
$ 190,225
 
 
$ (129,563 )
 
$ (1,990,952 )
 
$ (5,277,201 )
Net cash from the current year operations
 
$ (314,743 )
 
$ (88,243 )
 
$ (2,374,977 )
 
$ (4,919,238 )
Investing
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Common Stock
 
$ 9,875
 
 
$ -
 
 
$ 396,025
 
 
$ 2,444,714
 
Preferred A Stock
 
 
 
 
 
$ 0
 
 
 
 
 
 
$ 0
 
Net cash provided by investing activities
 
$ 9,875
 
 
$ 0
 
 
$ 396,025
 
 
$ 2,444,714
 
Financing
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Third Party Loan
 
$ 640
 
 
$ 2,514
 
 
$ 1,920
 
 
$ 301,295
 
Notes Payable
 
$ 268,332
 
 
$ -
 
 
$ 1,461,082
 
 
$ 1,837,200
 
Net cash provided by financing activities
 
$ 268,972
 
 
$ 2,514
 
 
$ 1,463,002
 
 
$ 2,138,495
 
Net change in cash and cash equivalents
 
$ (35,896 )
 
$ (85,729 )
 
$ (515,950 )
 
$ (336,029 )
Cash and cash equivalents, beginning of period
 
$ 104,372
 
 
$ 334,126
 
 
$ 584,426
 
 
$ 584,426
 
Cash and cash equivalents, end of period
 
$ 68,476
 
 
$ 248,397
 
 
$ 68,476
 
 
$ 248,397
 
 
The accompanying notes are an integral part of these financial statements.
 
 
F-4
 
  
POTNETWORK HOLDINGS, INC
STOCKHOLDERS' EQUITY
 
 
 
Preferred
 
 
Preferred
Share
 
 
Common
 
 
 
 
Surplus
 
 
 
Shares
 
 
Capital
 
 
Shares
 
 
Amount
 
 
(Deficit)
 
Common Stock as on Dec. 31, 2016
 
 
0
 
 
$ -
 
 
 
297,389,288
 
 
$ 88,573
 
 
$ (53,935 )
Triangular Merger
 
 
39,839
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$ 53,935
 
Shares Issued - Restricted
 
 
 
 
 
 
 
 
 
 
309,322,614
 
 
 
 
 
 
 
 
 
Shares Issued - Free
 
 
 
 
 
 
 
 
 
 
121,000,000
 
 
$ 363,000
 
 
 
 
 
Shares Issued - Reserve
 
 
 
 
 
 
 
 
 
 
(157,791,417 )
 
 
 
 
 
 
 
 
Net Profit (Loss)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$ 301,603
 
Balance as of Dec. 31, 2017
 
 
39,839
 
 
$ 400
 
 
 
569,920,485
 
 
$ 450,573
 
 
$ (2,279,739 )
Shares Issued
 
 
 
 
 
 
 
 
 
 
215,444,227
 
 
$ 2,718,467
 
 
 
 
 
Shares Cancelled
 
 
 
 
 
 
 
 
 
 
(216,000,000 )
 
 
 
 
 
 
 
 
Net Profit (Loss)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$ 242,634
 
Balance as of Dec. 31, 2018
 
 
39,839
 
 
$ 400
 
 
 
569,364,712
 
 
$ 3,169,040
 
 
$ (2,037,105 )
Shares Issued
 
 
 
 
 
 
 
 
 
 
131,471,672
 
 
$ 396,025
 
 
 
 
 
Net Profit (Loss)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$ (384,025 )
Balance as of September 30, 2019
 
 
34,289
 
 
$ 400
 
 
 
700,706,621
 
 
$ 3,565,065
 
 
$ (2,421,130 )
 
The accompanying notes are an integral part of these financial statements.
 
 
F-5
 
 
 
for the nine months ended 30th September, 2019
 
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS
 
PotNetwork Holdings, Inc. is a publicly traded holding company trading under the symbol “POTN”. The Company website is
www.potnetworkholding.com.
 
This Company was previously known as:
 
 
·
SND Auto Group, Inc. until 3-2017
 
·
PotNetwork Holdings, Inc. until 5-2016
 
·
United Treatment Centers, Inc. until 7-2015
 
·
Element Trading Holdings, Inc. until 3-2014
 
·
United Treatment Centers, Inc. until 10-2013
 
·
MyMedicalCD, Ltd. until 6-2008
 
·
Interactive Solutions Corp. until 11-2004
 
 
o
State of incorporation changed from Nevada to Wyoming in 11-2004
 
 
·
Araldica Wineries Ltd. until 2-2000
 
·
H P Capital Corp. until 9-1996
 
The Company has six (6) wholly-owned subsidiaries:
 
 
·
First Capital Venture Co., a Florida corporation which has as its wholly-owned subsidiary, Diamond CBD, Inc., a Delaware corporation. First Capital Venture Co. was acquired by the Company on January 31, 2017.
 
·
Blockchain Crypto Technology, Corp., an inactive Colorado corporation.
 
·
Grinder Distribution, Inc., an inactive Florida corporation
 
·
PNH Holdings, Inc., an inactive Colorado corporation
 
·
SND Auto Group, Inc., an inactive Colorado corporation
 
Since the acquisition of First Capital Venture Co., the focus of the Company has been the development of the business of Diamond CBD, Inc. PotNetwork Media Group, Inc. is an early stage company. All other subsidiaries are dormant having ceased operations. Hence, the financial statements reflect principally the business results of Diamond CBD business.
 
 
F-6
 
  
Diamond CBD, Inc. focuses on the research, development, and multinational marketing of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives.
 
Diamond CBD’s catalog can be found in
http://catalog.diamondcbd.com
.
 
Since the acquisition of First Capital Venture and Diamond CBD on January 31, 2017, Diamond CBD’s business has become the primary business of this Company. Diamond CBD is treated as a wholly owned subsidiary of the Company and the accounts of the subsidiary are presented in the Company’s consolidated statements eliminating inter-company transactions. In accordance with ASC 805-40-45 the consolidated financial statements represent the continuation of the financial statements of the wholly owned subsidiary except for its capital structure. The Company, being the legal acquiror, but the accounting acquiror, did not have significant assets or revenues prior to the consolidation.
 
Investment in the wholly owned subsidiary is accounted for in accordance with ASC 810.
 
In February 2018, the Company reversed ab initio the March 17, 2017 holding company reorganization. As a result, the Company re-assumed its prior name, PotNetwork Holdings, Inc. (with an “s” on Holding), while remaining a Colorado corporation. None of the acquisitions or the share capital structure was affected.
 
In February 2018, the shares issued pursuant to the reorganization were cancelled, no other adjustments had been made.
 
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
BASIS OF PRESENTATIONS:
The statements were prepared following generally accepted accounting principles of the United States of America which were consistently applied.
 
USE OF ESTIMATES:
Management uses estimates and assumptions in preparing these financial statements in accordance with U.S. generally accepted accounting principles. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses.
 
REVENUE RECOGNITION - DIAMOND CBD BUSINESS:
Revenue from the sale of goods is measured at fair value of the consideration received or receivable and is recognized in the statement of comprehensive income of the Company when significant risks and rewards of the ownership of the goods have been transferred to the buyers.
 
 
The Company applies the five-step model of revenue recognition under ASC 606 to the sales orders in the e-commerce platform. The following describes the Company’s process per each step (1-5) of ASC606:
 
 
Step 1:
"Identify the contract with a customer".
 
 
 
 
A.
The company’s ecommerce website is making the offer to the customer.
 
B.
The customer chooses the product(s) and quantities of each.
 
C.
The customer enters its credit card information.
 
D.
The contract between the company and the customer is concluded when the authorization is taken vis-a-vis the merchant account which processes the credit card payment.
  
 
Step 2:
“Identify the performance obligations in the contract”.
 
The company ships the merchandise and subsequently records the customer payment
 
 
Step 3:
“Determine the transaction price”.
 
The website states each product’s regular price, and applicable sale price which is the amount that the customer pays the company.
 
Step 4:
“Allocate the transaction price to the performance obligations in the contract”. The company’s e-commerce platform applies any quantity discount or other discount offered by the Company, automatically.
 
 
Step 5:
“Recognize revenue when the entity satisfies a performance obligation”.
 
The Company records the sale upon the order’s shipping, identified by a tracking number.
 
 
F-7
 
  
 
CASH AND CASH EQUIVALENTS:
Cash equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition and the balance cash in hand and the balance in bank accounts.
 
ACCOUNTS RECEIVABLE:
Accounts Receivable (AR) is the payment which the Company will receive from its customers who have purchased its goods & services in the last month of the year and on credit terms. Usually the credit period is short, approximately a few days.
   
 
ASSESSMENT OF COLLECTABILITY:
 
 
o
Receivables supervisor is authorized to collect delinquent accounts
 
 
o
The Treasurer has the authority to assign accounts to a third party for collection
 
 
o
Recording of Accounts Receivable: All amounts due on physical delivery of the merchandise from the drop-shipper, must be promptly recorded as an accounts receivable. Each account receivable must be recorded and maintained until payment is received or the recorded amount is written off or extinguished.
 
 
o
An adequate provision for doubtful accounts must be established. When all reasonable efforts fail to collect an account receivable and it has been approved for write off, the related provision for doubtful accounts should be reduced.
 
 
o
Control and Subsidiary Accounts: The accounting system incorporates control accounts, where applicable, to ensure the completeness and accuracy of individual accounts. The Receivables supervisor must maintain subsidiary accounts for individual debtors in a manner that discloses, at a given point in time, the aggregate amount owed by each debtor as well as individual amounts making up the aggregate amount. Monthly, the subsidiary accounts for each account receivable must be reconciled with the control account.
 
 
o
Checks that are returned from the bank as non-negotiable are assessed a returned cheque charge. If there are 2 cheques returned from the same customer within a month, no further cheques will be accepted from the customer unless the cheques are certified, until there is an acceptable payment history for a further one-year period.
 
 
o
Statements to Debtors: Statements must be issued to debtors, on a monthly basis, providing meaningful and concise information on the status of their debts.
 
 
o
Accounts receivable are considered overdue when a debtor does not pay or resolve the debt within 30 days from the invoice date or a written request for payment to the debtor.
 
 
o
All actions taken to collect overdue accounts must be documented.
 
 
o
If there is no response after the initial contact at the 30-day point (within a 30-day period - 60 days from date of invoice), accounts will be forwarded to Treasury Staff to take prompt and vigorous action to collect overdue accounts receivable.
 
 
o
Accounts receivable, in most cases, should be at least 30 days overdue (i.e., 60 days after invoice notification), before staff advises debtors that their accounts are overdue and that the accounts may be:
 
 
F-8
 
  
 
·
turned over to a private collection agency;
 
 
·
subject to legal action
 
 
·
credit privileges will be revoked; and/or account may be suspended.
 
 
PREPAID EXPENSES:
Prepaid expenses are future expenses that have been paid in advance. In other words, prepaid expenses are costs that have been paid but are not yet used up or have not yet expired. The company’s prepaid expenses is mostly advance payment to the drop shipper
 
 
PROPERTY AND EQUIPMENT:
As on the date of the financial statements, the Company does not hold any assets.
 
PROPERTY AND EQUIPMENT:
Property and equipment are stated at the written-down value [that is, after deducting depreciation from the cost]. This Company adapted the depreciation rates as provided in IRS publications, using the Modified Accelerated Cost Recovery System (MACRS). Computers and office equipment are considered as 5-year property. Office furniture and fixtures are 7-year property in MACRS and apply the 200% declining balance method over a GDS recovery period. Wherever possible, section 179 depreciation is also applied. However, the accumulated depreciation shall not exceed the actual cost at any point of time. As on the date of the financial statements, the Company does not hold any assets.
 
INTANGIBLE ASSETS
 
 
o
Initial Measurement:
Intangible asset acquisitions in which the consideration given is cash are measured by the amount of cash paid, which generally includes the transaction costs of the asset acquisition. However, if the consideration given is not in the form of cash (that is, in the form of noncash assets, liabilities incurred, or equity interests issued), measurement is based on either the cost which shall be measured based on the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is clearer and, thus, more reliably measurable.
 
 
o
Subsequent Measurement:
The Company accounts for its intangible assets under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Subtopic (“ASC”) 350-30-35 “Intangibles-- Goodwill and Other--General Intangibles Other than Goodwill-Subsequent Measurement”. Under this method the Company is required to test an indefinite-lived intangible asset for impairment on at least an annual basis. This is done by comparing the asset’s fair value with its carrying amount. If the carrying amount exceeds the asset’s fair value, the difference in those amounts is recognized as an impairment loss.
 
 
·
ASC 350 requires capitalizing any money spent on product development and product improvement. During the current year, money spent on product development is very little and is not significant.
 
FINANCIAL INSTRUMENTS:
For certain of the Company’s financial instruments, including cash, accrued expenses and short-term debt, the carrying amounts approximate their fair values due to their short maturities. We adopted ASC Topic 820, “Fair Value Measurements and Disclosures”, which requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, “Financial Instruments,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the balance sheets for current liabilities qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of valuation hierarchy are defined as follows:
 
Level 1:
Valuations consist of unadjusted quoted prices in active markets for identical assets and liabilities and has the highest priority;
Level 2:
Valuations rely on quoted prices in markets that are not active or observable inputs over the full term of the asset or liability;
Level 3:
Valuations are based on prices or third party or internal valuation models that require inputs that are significant to the fair value measurement and less observable and thus have the lowest priority.
 
 
F-9
 
  
Investments in subsidiaries:
The March 17, 2017 reorganization is referred as holding Company reorganization. The Company did not make any payment in cash or check in connection with the reorganization. First Capital Venture Co., the parent of Diamond CBD, Inc. is now the wholly owned subsidiary. The entire amount of current year profit is attributable to the business generated by this wholly owned subsidiary. As required under ASC 810, consolidated accounts are presented in this financial statement.
 
Redemption Right:
In 2017, this Company signed convertible promissory notes for $1,200,000. The convertible note has the redemption right, which reads as, “Notwithstanding any provision contained herein to the contrary including the conversion rights as set forth in this section, the Company shall be entitled, at any time prior to the expiration of five days from any notice of conversion, to repay this Note in full, plus interest, minus the credit accorded from prior payments, including from prior conversions, and avoid any further Note conversion and thus avoid the issuance of any additional shares of PotNetwork Holdings, Inc.” By this clause, no derivative liability exists. Further, these convertible promissory notes are exchanged for Common Stock Purchase Warrant, as mentioned supra.
 
NOTE 3 - GOING CONCERN
 
The financial statements are prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business.
 
Since PotNetwork Holdings, Inc. has no uncertainties as on the balance sheet date, the financial statements need no adjustments.
 
Since Diamond CBD’s business originated in 2015, it is considered as a business with limited operating history. Hence, this business is subject to all risks inherent in a developing business enterprise. Continued success depends on the problems, difficulties, complications, and delays frequently encountered in the competitive and regulatory environment in which it operates.
 
Since the CBD business is a burgeoning industry, there are no established entities whose business model Diamond CBD can follow or build upon.
 
Regulatory risk
: Hemp-based CBD is often confused with marijuana-based CBD which remains illegal under federal Law; although the Company maintains that its products are legal. Yet, this legal risk cannot be ignored.
 
Although Diamond CBD does not sell any marijuana-based CBD products, its products could be treated as being illegal by federal/state authorities and by consumers.
 
The Company is involved in a highly competitive industry where it may compete with numerous other companies who offer alternative methods or approaches, who may have far greater resources, more experience, and personnel perhaps more qualified than the Company does. Such resources, experience and personnel may provide a substantial competitive advantage to the competition.
 
NOTE 4 - DEFERRED TAX COMPUTATION:
The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes”. Under this method, income tax expense is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
 
 
F-10
 
 
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized.
 
ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for any of the reporting periods presented.
 
There was no income tax expense during this quarter. However, the availability of a net operating loss carryforward and the associated deduction, is subject to complex and restrictive federal income tax provisions as codified by Internal Revenue Code section 172 and related Treasury Regulations, all of which are subject to change and the availability of which can never be free from doubt.
 
The components of the deferred tax assets and liabilities are as follows:
 
 
 
30th Sep
2019
 
 
31st Dec
2018
 
Deferred tax assets:
 
 
 
 
 
 
Net operating loss carryovers
 
$ 2,421,130
 
 
$ 2,037,105
 
Stock-based compensation
 
 
-
 
 
 
-
 
Other temporary differences
 
 
-
 
 
 
-
 
Total deferred tax assets
 
 
2,421,130
 
 
 
2,037,105
 
Valuation allowance
 
 
(2,421,130 )
 
 
(2,037,105 )
Net deferred tax asset
 
$ -
 
 
$ -
 
 
NOTE 5 - INVENTORY DIAMOND CBD
 
This Company has arranged to buy the exact quantity from the suppliers, based on the customer orders and thereby has eliminated the need for holding inventory on hand at any point of time. Otherwise, this Company values the inventory at the lower of cost or market.
 
NOTE 6 - COMMITMENTS AND CONTINGENCIES:
There are no commitments and contingencies that exist at present, other than the legal disputes mentioned supra.
 
NOTE 7 - BUDGET & INTERNAL CONTROL PROCEDURES
 
 
·
Internal control procedures for inventory and cash control are being developed and implemented on an ongoing basis to ensure higher levels of performances.
 
·
Annual financial budget is reviewed by the Board of Directors.
 
·
Quarterly variance reports are reviewed by the Board of Directors.
 
NOTE 8 - CAPITAL STOCK
 
 
·
Common Stock
: Authorized 1,000,000,000 shares, $.00001 par value; and 700,836,384 issued and outstanding as on the balance sheet date. Further, this Company is obligated to issue additional shares to the noteholders mentioned here below.
 
·
Class A preferred stock
: Authorized 50,000 shares, $ .00001 par value; and 34,289 Issued and outstanding as on the balance sheet date. Designation details are in Document # 20181127754 filed with the Secretary of State, Colorado on February 13, 2018. On May 7, 2019, the Company filed with the Secretary of State, Colorado, amended Articles of Incorporation, under Document # 20171182699, whereby it changed the designation provisions of its Series A Preferred Stock.
 
 
F-11
 
 
NOTE 9 - LOAN FROM THIRD PARTIES
 
 
 
 
 
 
 
 
 
 
8
%
 
 
 
 
8
%
 
 
 
8
%
 
 
 
 
8
%
 
 
 
 
 
 
 
 
 
 
Interest
 
 
Interest
 
 
Interest
 
 
Interest
 
 
 
Loan
 
 
2018
 
 
2019 Q1
 
 
2019 Q2
 
 
2019 Q3
 
7/1/2016
 
$ 25,000
 
 
$ 28,000
 
 
$ 2,000
 
 
$ 30,000
 
 
$ 500
 
 
$ 30,500
 
 
$ 500
 
 
$ 31,000
 
 
$ 500
 
 
$ 31,500
 
7/1/2016
 
$ 7,000
 
 
$ 7,840
 
 
$ 560
 
 
$ 8,400
 
 
$ 140
 
 
$ 8,540
 
 
$ 140
 
 
$ 8,680
 
 
$ 140
 
 
$ 8,820
 
 
 
 
 
 
 
$ 35,840
 
 
$ 2,560
 
 
$ 38,400
 
 
$ 640
 
 
$ 39,040
 
 
$ 640
 
 
$ 39,680
 
 
$ 640
 
 
$ 40,320
 
  
NOTE 10 - NOTES PAYABLE
 
Payee: Sign N Drive
Principal Value: $1,850,000
Issue date: June 2, 2014, amended March 10, 2017
Terms: Interest Free, Fixed Conversion Rate at $.003 per share
Embedded Conversion Option: Given the fixed rate conversion price, no derivative liability calculation for the conversion option was deemed required.
There is no maturity date for this note.
 
The following table shows the amount of interest waived on annual basis through June 30, 2019:
 
Year
 
Interest
Waived
 
2017
 
$ 7,318
 
2018
 
 
4,351
 
2019 (through 9/30)
 
 
7,155
 
 
The following table sets forth the number of shares of common stock issued pursuant to each conversion under the Note:
 
 
 
Quantity
of Shares
 
 
Conversion
Price
 
 
Amount
Converted
 
August 13, 2014
 
 
161,127,812
 
 
 
0.00032
 
 
$ 51,561
 
April 4, 2016
 
 
2,750,000
 
 
 
0.004
 
 
 
11,000
 
August 2, 2016
 
 
4,500,000
 
 
 
0.0012
 
 
 
5,400
 
November 8, 2016
 
 
2,500,000
 
 
 
0.00152
 
 
 
3,800
 
December 22, 2016
 
 
10,000,000
 
 
 
0.00088
 
 
 
8,800
 
July 5, 2017
 
 
42,000,000
 
 
 
0.003
 
 
 
126,000
 
September 27, 2017
 
 
40,000,000
 
 
 
0.003
 
 
 
120,000
 
February 2, 2018
 
 
25,000,000
 
 
 
0.003
 
 
 
75,000
 
May 29, 2018
 
 
25,000,000
 
 
 
0.003
 
 
 
75,000
 
June 5, 2018
 
 
25,000,000
 
 
 
0.003
 
 
 
75,000
 
December 4, 2018
 
 
1,550,000
 
 
 
0.003
 
 
 
4,650
 
December 14, 2018
 
 
6,000,000
 
 
 
0.003
 
 
 
18,000
 
December 20, 2018
 
 
12,333,334
 
 
 
0.003
 
 
 
37,000
 
April 17, 2019
 
 
46,050,000
 
 
 
0.003
 
 
 
138,150
 
June 26, 2019
 
 
26,000,000
 
 
 
0.003
 
 
 
78,000
 
  
 
F-12
 
 
Per the above table:
 
$246,000 was converted into common stock in 2017; and
 
$284,650 was converted into common stock in 2018.  
 
Payee: Iliad Research & Trading LP
 
On October 25, 2018, the Company issued a Note in the face amount of $5,525,000 which accrues interest at the rate of 10% per annum. The note has an Original Issue Discount (OID) of $500,000. The Note and any interest thereon is convertible at a fixed rate of $0.45 per share of common stock or after 12 months, at a variable conversion rate, the “redemption conversion price” at the lower of the fixed rate of $.45 per share, or a discount to the market price as defined in the Note. The Note is comprised of five (5) tranches (each, a “Tranche”), consisting of (i) an Initial Tranche in an amount equal to $1,400,000.00 and any interest, costs, fees or charges accrued thereon or added thereto under the terms of this Note and the other Transaction Documents (as defined in the Purchase Agreement) (the ‘‘Initial Tranche”), and (ii) four (4) additional Tranches, one (l) in the amount of $1,375,000.00, one (l) in the amount of $550,000.00, and two (2) in the amount of $1,100,000.00, plus any interest, costs, fees or charges accrued thereon or added thereto under the terms of this Note and the other Transaction Documents.
 
 
·
$1,400,000 was received on 10/31/2018
 
 
·
$825,000 was received on 12/18/2018
 
 
·
$18,410 is the accrued interest for 2018
 
On February 8, 2019, the Company issued a Note in the face amount of $3,325,000 which accrues interest at the rate of 10% per annum. The note has an Original Issue Discount (OID) of $300,000. The Note and any interest thereon is convertible at a fixed rate of $0.45 per share of common stock or after 12 months, at a variable conversion rate, the “redemption conversion price” at the lower of the fixed rate of $.45 per share, or a discount to the market price as defined in the Note. The Note is comprised of three (3) tranches (each, a “Tranche”), consisting of (i) an Initial Tranche in an amount equal to $1,125,000.00 and any interest, costs, fees or charges accrued thereon or added thereto under the terms of this Note and the other Transaction Documents (as defined in the Purchase Agreement) (the ‘‘Initial Tranche”), and (ii) two (2) additional Tranches, one (l) in the amount of $500,000.00, and one (l) in the amount of $1,650,000.00, plus any interest, costs, fees or charges accrued thereon or added thereto under the terms of this Note and the other Transaction Documents.
 
 
·
$1,125,000 was received on 2/17/2019
 
 
·
$77,794 is the accrued interest through 3/31/19
 
 
·
$84,144 is the accrued interest from 4/1/2019 to June 30, 2019
 
 
·
$84,144 is the accrued interest from 6/1/2019 to Sep 30, 2019
 
 
F-13
 
 
NOTE 11 - Management Assertions on the 2 court cases regarding Convertible Promissory Notes of Predecessor
 
 
Mammoth West Corporation [case# 17 CH 778, 19th Circuit Court of Lake County, IL] and Southridge Partners II Limited Partnership [case# 3:17-cv-01925, Connecticut] each filed a civil complaint about its convertible promissory note (each referred to as a “Note”).
 
 
In each instance, the Note was issued not by the Company, but by the Company’s predecessor issuer, SND Auto Company Inc. (which predecessor issuer had changed its name before changing it back to SND Auto Group, Inc.). The Note was issued by SND Auto Company Inc., on June 13, 2016 and on July 18, 2016, respectively, for money paid to SND Auto Company Inc., at a time in which SND Auto Company Inc. was the public Company, operating in the automobile industry. However, on March 14, 2017, SND Auto Company Inc. formed the Company and engaged in a holding Company reorganization whereby the Company became the public entity while SND Auto Company Inc., became its subsidiary. The holding Company reorganization was an express condition of First Capital Venture Holdings Co., which is the parent Company to Diamond CBD, Inc. being acquired by the Company and thereby entering the CBD oil business. The acquisition would not have occurred without the holding Company reorganization. Following this acquisition and the holding Company reorganization, and following the Company becoming the public entity, the stock price increased significantly. In other words, the CBD oil company stock price (the Company, i.e., PotNetwork Holdings, Inc.) was much greater than the stock price of the automobile Company (SND Auto Company Inc.).
 
 
The plaintiff invested in an automobile Company, not in the CBD oil business. Yet, plaintiff wants to convert its Note issued by the automobile company into shares of the CBD oil Company, which was not the maker of the Note.
 
 
As of December 31, 2017, SND Auto Company Inc., not the Company, owed Mammoth West Corporation $7,280 and Southridge Partners II Limited Partnership $26,000, on the Notes, which obligations were never disputed by SND Auto Company Inc. (which SND Auto Group, Inc. agreed to pay each, in full).
 
 
The Company has maintained that these were not debts of the Company, and the holding Company reorganization was engaged in to assure as much, not to avoid payment, but instead, to isolate this debt from the new CBD oil business, SND Auto Company Inc. being a separate and distinct legal entity with its own assets and debts.
 
 
However, on February 7, 2018, the Company and its predecessor issuer, SND Auto Company Inc., unwound the March 14, 2017 holding Company reorganization.
 
 
Because of that unwinding, Company’s counsel agrees that the Company, the public entity, became liable for this SND Auto Group, Inc. Notes, but only as of the February 7, 2018 rewinding, not prior thereto.
 
 
So, at this point, the dispute between the parties surrounds the conversion price.
 
 
In each case, the terms of the Note entitle the plaintiff, as holder, to convert into shares of the maker’s common stock.
 
 
On March 28, 2017 and on April 24, 2017, the conversion notice in each case was issued, not to SND Auto Group, Inc., the maker, but to the Company, for shares of the Company’s common stock.
 
 
The terms of the Note entitle the plaintiff to payment in cash or in shares of the maker (SND Auto Group, Inc.), at a discount of 65% of the lowest trading price of the preceding 30 trading days.
 
 
Instead, however, the plaintiff has throughout, sought to convert into shares of the Company, at a fraction of a penny per share, or approximately 2,700,000 shares in each instance (as opposed to approximately 56,000 shares in each instance),
of the Company
, based on
SND Auto Group, Inc.
’s share price, when SND Auto Group, Inc. was the public Company, and prior to the Company even being in existence, let alone being public.
 
 
It is the Company’s position that the Company only became obligated for the Note (which is the obligation of the maker, SND Auto Group, Inc.), upon the unwinding of the reorganization, or as of February 7, 2018, when the Company’s stock price was considerably higher (and therefore obligated to issue far fewer shares in satisfaction of the conversion notice) than it was prior to the holding Company reorganization and the acquisition of First Capital Venture Holdings Co.
 
 
The Company intends to vigorously defend against this claim. The Company is confident in its position.
 
NOTE 12 - SUBSEQUENT EVENTS AFTER SEPTEMBER 30, 2019
 
NONE.
   
 
F-14
 
 


 
 
 
 
 
 
F-15
 


 
 
F-16
 
 
 
 
F-17
  
 
POTNETWORK HOLDINGS, INC
BALANCE SHEET
 
 
 
Dec. 31,
2018
 
 
Dec. 31,
2017
 
Assets
 
 
 
 
 
 
Current Assets
 
 
 
 
 
 
Cash/Bank Balances
 
$ 584,426
 
 
$ 254,571
 
Accounts Receivable
 
 
 
 
 
 
 
 
from Customers
 
$ 119,274
 
 
$ 138,341
 
from related parties
 
$ -
 
 
$ -
 
from others
 
$ -
 
 
$ -
 
Total Accounts Receivable
 
$ 119,274
 
 
$ 138,341
 
Advances - Drop Shipper
 
$ 4,289,928
 
 
$ 1,160,653
 
Prepaid Expenses
 
$ 220,902
 
 
$ 252,778
 
Total Current assets
 
$ 5,214,530
 
 
$ 1,806,343
 
TOTAL ASSETS
 
$ 5,214,530
 
 
$ 1,806,343
 
Liabilities
 
 
 
 
 
 
 
 
Current Liabilities
 
 
 
 
 
 
 
 
Payables
 
$ 469,821
 
 
$ 270,980
 
Current portion of Notes Payable, convertible
 
$ 306,150
 
 
$ 172,650
 
Total Current Liabilities
 
$ 775,971
 
 
$ 443,630
 
Long-term Liabilities
 
 
 
 
 
 
 
 
Loan from 3rd Party with interest
 
$ 38,400
 
 
$ 245,374
 
Notes Payable, convertible
 
$ 3,267,824
 
 
$ 2,946,105
 
Total Long-term liabilities
 
$ 3,306,224
 
 
$ 3,191,479
 
Total Liabilities
 
$ 4,082,195
 
 
$ 3,635,109
 
Stockholders’ Equity
 
 
 
 
 
 
 
 
Common Stock, $ 0.00001 par value, 1,000,000,000 shares authorized, 569,364,712 shares Issued and outstanding as of December 31, 2018 and 569,920,485 shares Issued and outstanding as of December 31, 2017
 
$ 3,169,040
 
 
$ 450,573
 
Preferred Stock Class A, $ 0.00001 par value, 50,000,000 shares authorized, 39,839 shares Issued and outstanding as of December 31, 2018 and December 31, 2017
 
$ 400
 
 
$ 400
 
Additional Paid-in Capital
 
 
 
 
 
$ 1,463,131
 
Retained Earnings
 
$ (2,037,105 )
 
$ (2,279,739 )
Total Stockholders’ Equity
 
$ 1,132,335
 
 
$ (1,828,766 )
Total Liabilities & Equity
 
$ 5,214,530
 
 
$ 1,806,343
 
 
The accompanying notes are an integral part of these financial statements.
 
 
F-18
 
 
POTNETWORK HOLDINGS, INC
INCOME STATEMENT
 
 
 
Year Ended
 
 
Year Ended
 
 
 
Dec. 31,
2018
 
 
Dec. 31,
2017
 
 
 
 
 
 
 
 
Revenue
 
 
 
 
 
 
Sales
 
$ 25,583,761
 
 
$ 14,388,204
 
Cost of goods sold
 
$ 16,624,328
 
 
$ 9,318,271
 
Gross profit
 
$ 8,959,433
 
 
$ 5,069,933
 
 
 
 
 
 
 
 
 
 
Operating expenses
 
 
 
 
 
 
 
 
Research and development
 
$ -
 
 
$ 524,720
 
Sales & Marketing
 
$ 7,894,819
 
 
$ 3,491,555
 
General & Administrative Expenses
 
$ 811,420
 
 
$ 735,175
 
Total operating expenses
 
$ 8,706,239
 
 
$ 4,751,450
 
 
 
 
 
 
 
 
 
 
Financing expenses
 
 
 
 
 
 
 
 
Interest Exp
 
$ 10,560
 
 
$ 16,880
 
Total Financing expenses
 
$ 10,560
 
 
$ 16,880
 
 
 
 
 
 
 
 
 
 
Total expenses
 
$ 8,716,799
 
 
$ 4,768,330
 
 
 
 
 
 
 
 
 
 
Profit (Loss) before Income Tax
 
$ 242,634
 
 
$ 301,603
 
Provision for Income Tax
 
$ -
 
 
$ -
 
Net Profit (Loss)
 
$ 242,634
 
 
$ 301,603
 
 
 
 
 
 
 
 
 
 
Earnings per share
 
$ 0.0003
 
 
$ 0.0005
 
Basic and diluted
 
$ 0.0003
 
 
$ 0.0005
 
 
 
 
 
 
 
 
 
 
Basic and diluted weighted average common shares outstanding
 
 
569,364,712
 
 
 
569,920,485
 
 
The accompanying notes are an integral part of these financial statements.
 
 
F-19
 
 
POTNETWORK HOLDINGS, INC
STOCKHOLDERS’ EQUITY
 
 
 
Pref Shares
 
 
Preference share capital
 
 
Common Shares
 
 
Equity
 
 
Surplus
(Deficit)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance as on Dec. 31, 2016
 
 
0
 
 
$ -
 
 
 
297,389,288
 
 
$ 87,573
 
 
$ (53,935 )
Triangular Merger
 
 
39,839
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$ 53,935
 
Shares Issued - Restricted
 
 
 
 
 
 
 
 
 
 
309,322,614
 
 
 
 
 
 
 
 
 
Shares Issued - Free
 
 
 
 
 
 
 
 
 
 
121,000,000
 
 
$ 363,000
 
 
 
 
 
Shares Issued - Reserve
 
 
 
 
 
 
 
 
 
 
(157,791,417 )
 
 
 
 
 
 
 
 
Net Profit (Loss)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$ 301,603
 
Balance as on Dec. 31, 2017
 
 
39,839
 
 
$ 400
 
 
 
569,920,485
 
 
$ 450,573
 
 
$ (2,279,739 )
Shares Issued
 
 
 
 
 
 
 
 
 
 
215,444,227
 
 
$ 2,718,467
 
 
 
 
 
Shares Cancelled
 
 
 
 
 
 
 
 
 
 
(216,000,000 )
 
 
 
 
 
 
 
 
Net Profit (Loss)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
$ 242,634
 
Balance as of Dec. 31, 2018
 
 
39,839
 
 
$ 400
 
 
 
569,364,712
 
 
$ 3,169,040
 
 
$ (2,037,105 )
 
The accompanying notes are an integral part of these financial statements.
 
 
F-20
 
 
POTNETWORK HOLDINGS, INC
CASH FLOWS STATEMENT
 
 
 
Year Ended
 
 
Year Ended
 
 
 
Dec. 31, 2018
 
 
Dec. 31, 2017
 
Operations
 
 
 
 
 
 
Net Income (Loss)
 
$ 242,634
 
 
$ 290,720
 
Adjustments to reconcile net income (loss)
 
 
 
 
 
 
 
 
Advances & Accounts Receivable
 
$ (3,078,333 )
 
$ 1,483,264
 
Payable
 
$ 198,841
 
 
$ (63,629 )
Total Adjustments to reconcile net income (loss)
 
$ (2,879,492 )
 
$ 1,419,635
 
Net cash from the current year
operations
 
$ (2,636,858 )
 
$ 1,710,355
 
Investing
 
 
 
 
 
 
 
 
Common Stock
 
$ 2,718,467
 
 
$ (450,573 )
Preferred A Stock
 
 
 
 
 
$ (400 )
Additional Capital
 
$ (1,463,131 )
 
$ 675,814
 
Net cash provided by
investing
activities
 
$ 1,255,336
 
 
$ 224,841
 
Financing
 
 
 
 
 
 
 
 
Third Party Loan
 
$ (206,974 )
 
$ (172,641 )
Notes Payable
 
$ 1,918,350
 
 
$ (1,655,624 )
Net cash provided by
financing
activities
 
$ 1,711,376
 
 
$ (1,828,265 )
Net change in cash and cash equivalents
 
$ 329,854
 
 
$ 106,931
 
Cash and cash equivalents, beginning of period
 
$ 254,571
 
 
$ 147,640
 
Cash and cash equivalents, end of period
 
$ 584,426
 
 
$ 254,571
 
 
The accompanying notes are an integral part of these financial statements.
 
 
F-21
 
 
 
PotNetworkHolding.com
DiamondCBD.com
 
Notes on Accounts to the financial statements for the year, 2018
 
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS
 
PotNetwork Holdings, Inc. is a publicly traded holding company trading under the symbol POTN. The Company website is
www.potnetworkholding.com.
 
This Company was previously known as:
 
·
SND Auto Group, Inc. until 3-2017
·
PotNetwork Holdings, Inc. until 5-2016
·
United Treatment Centers, Inc. until 7-2015
·
Element Trading Holdings, Inc. until 3-2014
·
United Treatment Centers, Inc. until 10-2013
·
MyMedicalCD, Ltd. until 6-2008
·
Interactive Solutions Corp. until 11-2004
 
o
State of incorporation changed from Nevada to Wyoming in 11-2004
 
·
Araldica Wineries Ltd. until 2-2000
·
H P Capital Corp. until 9-1996
 
The Company has three (3) wholly-owned subsidiaries:
 
·
First Capital Venture Co., a Florida corporation which has as its wholly-owned subsidiary, Diamond CBD, Inc., a Delaware corporation. First Capital Venture Co. was acquired by the Company on January 31, 2017.
·
PotNetwork Media Group, Inc., a Nevada corporation, the owner and operator of
www.Potnetwork.com
as a digital business magazine focusing on the cannabis industry, which was acquired under a stock purchase agreement.
·
Blockchain Crypto Technology, Corp., an inactive Colorado corporation.
·
Grinder Distribution, Inc., an inactive Florida corporation.
·
PNH Holdings, Inc., an inactive Colorado corporation
·
SND Auto Group, Inc., an inactive Colorado corporation
 
Since the acquisition of First Capital Venture Co., the focus of the Company has been the development of the business of Diamond CBD, Inc. PotNetwork Media Group, Inc., is an early stage company. All other subsidiaries are dormant, having ceased operations. Hence, the financial statements reflect principally the business results of Diamond CBD business.
 
Diamond CBD, Inc. focuses on the research, development, and multinational marketing of premium hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives.
 
 
F-22